HUMAN ALPHA-1-GLYCOPROTEIN AND ITS INTERACTIONS WITH DRUGS^†,‡

REFERENCES

• Dayton P. G., Israili Z. H., Perel J. M. Influence of Binding on Drug Metabolism and Distribution. Ann. NY Acad. Sci. 1973; 226: 172–194
   PubMed Web of Science ®Google Scholar
• Levy G. Effect of Plasma Binding of Drugs on Duration and Intensity of Pharmacological Activity. J. Pharm. Sci. 1976; 65: 1264–1265
   PubMed Web of Science ®Google Scholar
• Wilkinson G. R. Plasma and Tissue Binding Considerations in Drug Disposition. Drug Metab. Rev. 1983; 14: 427–465
   PubMed Web of Science ®Google Scholar
• Tillement J.-P., Houin G., Zini R., Urien S., Albengres E., Barre J., Lecomte M., d'Athis P., Sebille B. The Binding of Drugs to Blood Plasma Macromolecules: Recent Advances and Therapeutic Significance. Advances in Drug Research, B. Testa. Academic Press, London 1984; 13: 59–94
   Google Scholar
• Belpaire F. M., Bogaert M. G. Pharmacokinetic and Pharmacodynamic Consequences of Altered Binding of Drugs to Alpha 1-Acid Glycoprotein. Prog. Clin. Biol. Res. 1989; 300: 337–350
   PubMedGoogle Scholar
• Plafsky K. M., Borgå O. Plasma Protein Binding of Basic Drugs. II. Importance of Alpha1-Acid Glycoprotein for Interindividual Variation. Clin. Pharmacol. Ther. 1977; 22: 545–549
   PubMed Web of Science ®Google Scholar
• Piafsky K. M. Disease-Induced Changes in the Plasma Binding of Basic Drugs. Clin. Pharmacokinet. 1980; 5: 246–262
   PubMed Web of Science ®Google Scholar
• Ganguly M., Carnighan R. H., Westphal U. Steroid–Protein Interactions. XIV. Interaction Between Human Alpha 1-Acid Glycoprotein and Progesterone. Biochemistry 1967; 6: 2803–2814
   PubMed Web of Science ®Google Scholar
• Westphal U. Interaction of Progesterone and Other Steroids with Alpha 1-Acid Glycoprotein. Monographs on Endocrinology, F. Gross, A. Labhart, T. Mann, L. T. Samuels, J. Zander. Springer-Verlag, New York 1971; 4: 375–434
   Google Scholar
• Paxton J. W. Drug Binding to Plasma Proteins. NZ Med. J. 1985; 98: 245–248
   PubMedGoogle Scholar
• Lima J. J., Boudoulas H., Blanford M. Concentration-Dependence of Disopyramide Binding to Plasma Protein and Its Influence on Kinetics and Dynamics. J. Pharmacol. Exp. Ther. 1981; 219: 741–747
   PubMed Web of Science ®Google Scholar
• Pacifici G. M., Viani A., Taddeucci-Brunelli G., Rizzo G., Carrai M., Schulz H. U. Effects of Development, Aging, and Renal and Hepatic Insufficiency as Well as Hemodialysis on the Plasma Concentrations of Albumin and Alpha 1-Acid Glycoprotein: Implications for Binding of Drugs. Ther. Drug. Monit. 1986; 8: 259–263
   PubMed Web of Science ®Google Scholar
• Meijer D. K., van der Sluijs P. The Influence of Binding to Albumin and Alpha 1-Acid Glycoprotein on the Clearance of Drugs by the Liver. Pharmaceutisch Weekblad—Scientific Edition 1987; 9: 65–74
   PubMedGoogle Scholar
• Schley J., Muller-Oerlinghausen B. The Binding of Chemically Different Psychotropic Drugs to Alpha 1-Acid Glycoprotein. Pharmacopsychiatry 1983; 16: 82–85
   Google Scholar
• Borgå O., Piafsky K. M., Nilsen O. G. Plasma Protein Binding of Basic Drugs. I. Selective Displacement from Alpha 1-Acid Glycoprotein by Tris(2-butoxyethyl) Phosphate. Clin. Pharmacol. Ther. 1977; 22: 539–544
   PubMed Web of Science ®Google Scholar
• Kremer J. M.H., Wilting J., Janssen L. H.M. Drug Binding to Human Alpha 1-Acid Glycoprotein in Health and Disease. Pharmacol. Rev. 1988; 40: 1–47
   PubMed Web of Science ®Google Scholar
• Kaliszan R., Nasal A., Turowski M. Quantitative Structure–retention Relationships in the Examination of the Topography of the Binding Site of Antihistaminic Drugs on Alpha 1-Acid Glycoprotein. J. Chromatogr. A 1996; 722: 25–32
   PubMed Web of Science ®Google Scholar
• Kageyama S., Anderson B. D., Hoesterey B. L., Hayashi H., Kiso Y., Flora K. P., Mitsuya H. Protein Binding of Human Immunodeficiency Virus Protease Inhibitor KNI-272 and Alteration of Its In Vitro Antiretroviral Activity in the Presence of High Concentrations of Proteins. Antimicrob. Agents Chemother. 1994; 38: 1107–1111
   PubMed Web of Science ®Google Scholar
• Bilello J. A., Bilello P. A., Pritchard M., Robins T., Drusano G. L. Reduction of the In Vitro Activity of A-77003, an Inhibitor of Human Immunodeficiency Virus Protease, by Human Serum Alpha 1-Acid Glycoprotein. J. Infect. Dis. 1995; 171: 546–551
   PubMed Web of Science ®Google Scholar
• Bilello J. A., Bilello P. A., Stellrecht K., Leonard J., Norbeck D. W., Kempf D. J., Robins T., Drusano G. L. Human Serum Alpha 1-Acid Glycoprotein Reduces Uptake, Intracellular Concentration, and Antiviral Activity of A-80987, an Inhibitor of the Human Immunodeficiency Virus Type 1 Protease. Antimicrob. Agents Chemother. 1996; 40: 1491–1497
   PubMed Web of Science ®Google Scholar
• Bryant M., Getman D., Smidt M., Marr J., Clare M., Dillard R., Lansky D., DeCrescenzo G., Heintz R., Houseman K., et al. SC-52151, a Novel Inhibitor of the Human Immunodeficiency Virus Protease. Antimicrob. Agents Chemother. 1995; 39: 2229–2234
   PubMed Web of Science ®Google Scholar
• Livington D. J., Pazhanisamy S., Porter D. J., Partaledis J. A., Tung R. D., Painter G. R. Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-human Immunodeficiency Virus Therapy. J. Infect. Dis. 1995; 172: 1238–1245
   PubMed Web of Science ®Google Scholar
• Kiriyama A., Nishiura T., Ishino M., Yamamoto Y., Ogita I., Kiso Y., Takada K. Binding Characteristics of KNI-272 to Plasma Proteins, a New Potent Tripeptide HIV Protease Inhibitor. Biopharm. Drug Dispos. 1996; 17: 739–751
   PubMed Web of Science ®Google Scholar
• Barry M., Gibbons S., Back D., Mulcahy F. Protease Inhibitors in Patients with HIV Disease. Clinically Important Pharmacokinetic Considerations. Clin. Pharmacokinet. 1997; 32: 194–209
   PubMed Web of Science ®Google Scholar
• Veronese L., Rautaurean J., Sadler B. M., Gillotin G., Petite J. P., Pilligand B. P., Delvaux M., Masliah C., Fosse F., Lou Y., Stein D. S. Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic Function. Antimicrob. Agents Chemother. 2000; 44: 821–826
   PubMed Web of Science ®Google Scholar
• Schmid K. Alpha1-Acid Glycoprotein. The Plasma Proteins: Structure, Function and Genetic Control, F. W. Putnam. 2nd Ed., Academic Press, New York 1975; 1: 183–228
   Google Scholar
• Hao Y. L., Wickerhauser M. Development of Large-Scale Fractionation Methods. IV. A Simple Method for the Large-Scale Preparation of Alpha 1-Acid Glycoprotein. Biochim. Biophys. Acta 1973; 322: 99–108
   PubMed Web of Science ®Google Scholar
• Lentner C. Documenta Geigy Scientific Tables. Physical Chemistry, Blood, Somatometric Data. 8th Ed., Ciba Geigy Corporation, West Caldwell, NJ 1984; 3: 135–137, 140–142
   Google Scholar
• Schmid K. Human Alpha 1-Acid Glycoprotein—Biochemical Properties, the Amino Acid Sequence and the Structure of the Carbohydrate Moiety, Variants and Polymorphism. Prog. Clin. Biol. Res. 1989; 300: 7–22
   PubMedGoogle Scholar
• Koj A. Acute Phase Reactants. Their Synthesis, Turnover, and Biological Significance. Structure and Function of Plasma Proteins, A. C. Allison. Plenum, London 1974; 73–125
   Google Scholar
• McPherson A., Friedman M. L., Halsall H. B. Crystallization of Alpha 1-Acid Glycoprotein. Biochem. Biophys. Res. Commun. 1984; 124: 619–624
   PubMed Web of Science ®Google Scholar
• Schmid K., Emura J., Schmid M. F., Stevens R. L., Nimberg R. B. Sequence Comparison of Human Plasma Alpha 1-Acid Glycoprotein and the Immunoglobulins. Int. J. Peptide Proteins 1978; 11: 42–48
   PubMed Web of Science ®Google Scholar
• Board P. G., Jones I. M., Bentley A. K. Molecular Cloning and Nucleotide Sequence of Human Alpha 1-acid Glycoprotein cDNA. Gene 1986; 44: 127–131
   PubMed Web of Science ®Google Scholar
• Oleinikov V. A., Feofanov A. V., Shiian S. D., Tuzikov A. B., Kriukov E. Iu., Ianul' A. I., Bovin N. B., Nabiev I. R. IR Surface Enhanced Raman Spectroscopy for Characterization of Structural Characterization of Carbon Chains in Alpha-1-Acid Glycoprotein and Pseudoglycoproteins. Bioorg. Khim. 1998; 24: 412–421, (in Russian)
   PubMed Web of Science ®Google Scholar
• Schwarzmann G. O.H., Hatcher V. B., Jeanloz R. W. Purification and Structure Elucidation of Several Carbohydrate Side Chains from Alpha 1-Acid Glycoproteins. J. Biol. Chem. 1978; 253: 6983–6987
   PubMed Web of Science ®Google Scholar
• Webb G. C., Earle M. E., Merritt C., Board P. G. Localization of Human Alpha 1-Acid Glycoprotein Genes to 9q31–34.1. Cytogenet. Cell Genet. 1988; 47: 18–21
   PubMedGoogle Scholar
• Dente L. Human Alpha 1-Acid Glycoprotein Genes. Prog. Clin. Biol. Res. 1989; 300: 85–98
   PubMedGoogle Scholar
• Eap C. B., Baumann P. The Genetic Polymorphism of Human Alpha 1-Acid Glycoprotein. Prog. Clin. Biol. Res. 1989; 300: 111–125
   PubMedGoogle Scholar
• Yuasa I., Umetsu K., Vogt U., Nakamura H., Nanba E., Tamaki N., Irizawa Y. Human Orosomucoid Polymorphism: Molecular Basis of the Three ORM1 Alleles, ORM1*F1, ORM1*F2 and ORM*S. Hum. Genet. 1997; 99: 393–398
   PubMed Web of Science ®Google Scholar
• Pervaiz S., Brew K. Homology and Structure–Function Correlations Between Alpha 1-Acid Glycoprotein and Serum Retinol-Binding Protein and Its Relatives. FASEB J. 1987; 1: 209–214
   PubMed Web of Science ®Google Scholar
• Toh H., Hayashida H., Kikuno R., Yasunaga T., Miyata T. Sequence Similarity Between EGF Receptor and Alpha-1-Acid Glycoprotein. Nature (London) 1985; 314: 199
   PubMed Web of Science ®Google Scholar
• Ochi Y., Fujiyama Y., Hosoda S., Miyazaki T., Yoshimura M., Hachiya T., Kajita Y. Immunological Similarity of CEA with Alpha 1-Acid Glycoprotein (Orosomucoid). Clin. Chim. Acta 1982; 122: 145–160
   PubMed Web of Science ®Google Scholar
• Berger E. G., Alpert E., Schmid K., Isselbacher K. J. Immunohistochemical Localization of Alpha1-Acid Glycoprotein in Human Liver Parenchymal Cells. Histochemistry 1977; 51: 293–296
   PubMedGoogle Scholar
• Daveau M., Liautard J., Gaillard J. P., Hiron M., Brochier J., Lebreton J. P. II-6 Induced Changes in Synthesis of Alpha 1-Acid Glycoprotein in Human Hepatoma Hep3B Cells are Distinctively Regulated by Monoclonal Antibodies Directed Against Different Epitopes of II-6 Receptor (gp80). Eur. Cytokine Network 1994; 5: 601–608
   PubMed Web of Science ®Google Scholar
• Cayol M., Tauveron I., Rambourdin F., Prugnaud J., Gachon P., Thieblot P., Grizard J., Obled C. Whole-Body Protein Turnover and Hepatic Protein Synthesis Are Increased by Vaccination in Man. Clin. Sci. (Colch.) 1995; 89: 389–396
   Google Scholar
• Sorensson J., Matejha G. L., Ohlson M., Haraldsson B. Human Endothelial Cells Produce Orosomucoid, an Important Component of the Capillary Barrier. Am J. Physiol. 1999; 276: H530–H534
   PubMed Web of Science ®Google Scholar
• Fournier T., Bouach N., Delafosse C., Crestani B., Aubier M. Inducible Expression and Expression of the Alpha 1-Acid Glycoprotein Gene by Alveolar Macrophages: Prostaglandin E2 and Cyclic AMP Act as New Positive Stimuli. J. Immunol. 1999; 163: 2883–2890
   PubMed Web of Science ®Google Scholar
• Crestani B., Rolland C., Lardeux B., Fournier T., Bernuau D., Pous C., Vissuzaine C., Li L., Aubier M. Inducible Expression of the Alpha 1-Acid Glycoprotein by Rat and Human Type II Alveolar Epithelial Cells. J. Immunol. 1998; 160: 4596–4605
   PubMed Web of Science ®Google Scholar
• Ashwell G. J., Steer C. J. Hepatic Recognition and Catabolism of Serum Glycoproteins. J. Am. Med. Assoc. 1981; 246: 2358–2364
   PubMed Web of Science ®Google Scholar
• Carpentier V., Midoux P., Monsigny M., Roche A. C. Endocytosis of Alpha 1-Acid Glycoprotein Variants by Human Monocytic Lineage Cells. Biol. Cell 1993; 77: 187–193
   PubMed Web of Science ®Google Scholar
• Weisman S., Goldsmith B., Winzler R., Lepper M. H. Turnover of Plasma Orosomucoid in Man. J. Lab. Clin. Med. 1961; 57: 7–15
   Google Scholar
• Jakab L., Kalabay L. The Acute Phase Reaction Syndrome: The Acute Phase Reactants. Acta Microbiol. Immunol. Hung. 1998; 45: 409–418
   PubMedGoogle Scholar
• Rolan P. E., Muirhead M., Clarkson A. R. Increased Plasma Levels of Alpha 1-Acid Glycoprotein in Chronic Renal Failure Are Unlikely to Be Due to Decreased Renal Elimination [Letter]. Nephron 1986; 42: 345–346
   PubMedGoogle Scholar
• Mackiewicz A., Khan M. A., Reynolds T. L., van der Linden S., Kushner I. Serum IgA, Acute Phase Proteins, and Glycosylation of Alpha 1-Acid Glycoprotein in Ankylosing Spondylitis. Ann. Rheum. Dis. 1989; 48: 99–103
   PubMed Web of Science ®Google Scholar
• Mackiewics A., Mackiewics K. Glycoforms of Serum Alpha 1-Acid Glycoprotein as Markers of Inflammation and Cancer. Glycoconjugate J. 1995; 12: 241–247
   PubMed Web of Science ®Google Scholar
• Adamian A. J., Guliaev A. A., Ivanina T. A., Evteeva E. A., Samsonov V. T. Acute Phase Response and Plasma Proteins in Acute Cholecystitis. Klin. Lab. Diagn. 1997; 11: 8–10, (in Russian)
   PubMedGoogle Scholar
• Kushner I. The Regulation of the Acute Phase Response by Cytokines. Perspect. Biol. Med. 1993; 36: 611–622
   PubMed Web of Science ®Google Scholar
• Bourantas K. L., Dakelos G. N., Makis A., Chaidos A., Tsiara S., Mavrides A. Acute Phase Proteins and Interleukins in Steady State Sickle Cell Disease. Eur. J. Haematol. 1998; 61: 49–54
   PubMed Web of Science ®Google Scholar
• Banks R. E., Forbes M. A., Storr M., Higginson J., Thompson D., Raynes J., Illingsworth J. M., Perren T. J., Selby P. J., Whicher J. T. The Acute Phase Protein Response in Patients Receiving Subcutaneous IL-6. Clin. Exp. Immunol. 1995; 102: 217–223
   PubMed Web of Science ®Google Scholar
• Kulkarni A. B., Reinke R., Feigelson P. Acute Phase Mediators and Glucocorticoids Elevate Alpha 1-Acid Glycoprotein Gene Transcription. J. Biol. Chem. 1985; 260: 15,386–15,389
   Google Scholar
• Baumann H., Morella K. K., Campos S. P., Cao Z., Jahreis G. P. Role of CAATEnhancer Binding Protein Isoforms in the Cytokine Regulation of Acute-Phase Plasma Protein Genes. J. Biol. Chem. 1992; 267: 19,744–19,751
   Google Scholar
• Lee Y. M., Miau L. H., Chang C. J., Lee S. C. Transcriptional Induction of the Alpha 1-Acid Glycoprotein (AGP) Gene by Synergistic Interaction of Two Alternative Activator Forms of AGP/Enhancer-Binding Protein (C/EBP Beta) and NF-kappaB or Nopp 140. Mol. Cell Biol. 1996; 16: 4257–4263
   PubMed Web of Science ®Google Scholar
• Chang C. J., Chen Y. L., Lee S. C. Coactivator TIF1beta Interacts with Transcription Factor C/EBPbeta and Glucocorticoid Receptor to Induce Alpha 1-Acid Glycoprotein Gene Expression. Mol. Cell Biol. 1998; 18: 5880–5887
   PubMed Web of Science ®Google Scholar
• Shiin S. D., Khaidukov S. V., Pukhal'skii A. L., Toptygina A. P., Bovin N. V. The Interaction of Peripheral Blood Leukocytes with Alpha 1-Acid Glycoprotein, Its Carbohydrate Chains and Neoglycoconjugates. Gematol. Transfuziol. 1996; 41: 24–29, (in Russian)
   PubMed Web of Science ®Google Scholar
• Andersen U. O., Bög-Hansen T. C., Kirkeby S. Lectin-like Receptors for Alpha 1-Acid Glycoprotein in the Epithelium of the Rat Prostate Gland and Seminal Vesicles. Prostate 1996; 29: 356–361
   PubMed Web of Science ®Google Scholar
• Andersen U. O., Bög-Hansen T. C., Kirkeby S. Zonal Variation in the Distribution of an Alpha 1-Acid Glycoprotein Glycoform in Human Adrenal Cortex. Acta Histochem. 1999; 101: 113–119
   PubMed Web of Science ®Google Scholar
• Andersen U. O., Bög-Hansen T. C., Kirkeby S. Zonal Variation in the Distribution of an Alpha 1-Acid Glycoprotein Receptorin Human Adrenal Cortex. Acta Histochem. 1999; 101: 113–119
   PubMed Web of Science ®Google Scholar
• Busby T. F., Ingham K. C. Thermal Stability and Ligand-Binding Properties of Human Alpha 1-Acid Glycoprotein (Orosomucoid) as Determined with Fluorescent Probes. Biochim. Biophys. Acta 1986; 871: 61–71
   PubMed Web of Science ®Google Scholar
• Mosley A. K., Brouwer K. L.R. Heat Treatment of Human Serum to Inactivate HIV Does Not Alter Protein Binding of Selected Drugs. Ther. Drug Monit. 1997; 19: 477–479
   PubMed Web of Science ®Google Scholar
• Shrake A., Finlayson J. S., Ross P. D. Thermal Stability of Human Albumin Measured by Differential Scanning Calorimetry. Vox Sang. 1984; 47: 7–18
   PubMed Web of Science ®Google Scholar
• Tenser J., Thysell H., Andersson K., Grubb A. Long-Term Stability of Albumin, Protein HC, Immunoglobulin, Kappa- and Lambda-Chain-Immunoreactants, Orosomucoid and Alpha 1-Antitrypsin in Urine Stored at −20 degrees C. Scand. J. Urol. Nephrol. 1997; 31: 677–671
   Google Scholar
• Zhou H. H., Adedoyin A., Wilkinson G. R. Differences in Plasma Binding of Drugs Between Caucasians and Chinese Subjects. Clin. Pharmacol. Ther. 1990; 48: 10–17
   PubMed Web of Science ®Google Scholar
• Halsall H. B., Kirley T. L. The Denaturation of Orosomucoid. Arch. Biochem. Biophys. 1982; 216: 392–399
   PubMed Web of Science ®Google Scholar
• Barclay G. R., Flewett T. H., Keller E., Halsall H. B., Spragg S. P. Effect of Polymerized Orosomucoid on Some Strains of Influenza Virus. Biochem. J. 1969; 111: 353–357
   PubMed Web of Science ®Google Scholar
• Sager G., Bratlid H., Little C. Binding of Catecholamines to Alpha 1-Acid Glycoprotein, Albumin and Lipoproteins in Human Serum. Biochem. Pharmacol. 1987; 36: 3607–3612
   PubMed Web of Science ®Google Scholar
• de Vera N., Cristofol R. M., Rodriguez Farre E. Protein Binding and Stability of Norepinephrine in Human Blood Plasma. Involvement of Prealbumin, Alpha 1-Acid Glycoprotein and Albumin. Life Sci. 1988; 43: 1277–1286
   PubMed Web of Science ®Google Scholar
• Frantz M., Jung M. L., Ribereau-Gayon G., Anton R. Modulation of Mistletoe (Viscum album L.) Lectins Cytotoxicity by Carbohydrate and Serum Glycoproteins. Arzneimittelforschong 2000; 50: 471–478
   PubMed Web of Science ®Google Scholar
• Moore D. F., Rosenfeld M. R., Gribbon P. M., Winlove C. P., Tsai C. M. Alpha-1-acid Glycoprotein (AAG, orosomucoid) Glycoprotein: Interactions with Bacterial Lipopolysaccharide and Protection from Sepsis. Inflammation 1997; 21: 69–82
   PubMed Web of Science ®Google Scholar
• Muchitsch E. M., Auer W., Pichler L. Effect of Alpha 1-Acid Glycoprotein in Different Rodent Models of Shock. Fundam. Clin. Pharmacol. 1998; 12: 173–181
   PubMed Web of Science ®Google Scholar
• Athamna A., Kramer M. R., Kahane I. Adherence of Mycoplasma pneumoniae to Human Alveolar Macrophages. FEMS Immunol. Med. Microbiol. 1996; 15: 135–141
   PubMed Web of Science ®Google Scholar
• Rabehi L., Ferriere F., Saffar L., Gattegno L. Alpha 1-Acid Glycoprotein Binds Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Glycoprotein via NLinked Glycans. Glycoconjugate J. 1995; 12: 7–16
   PubMed Web of Science ®Google Scholar
• Superti F., Marziano M. L., Tinari A., Donelli G. Effect of Polyanions on the Infectivity of SA-II Rotavirus in LCC-MK2 Cells. Comp. Immunol. Microbiol. Infect. Dis. 1993; 16: 55–62
   PubMed Web of Science ®Google Scholar
• Su S. J., Yang B. C., Wang Y. S., Yeh T. M. Alpha 1-Acid Glycoprotein-Induced Tissue Necrosis Factor-alpha Secretion on Human Monocytes Is Enhanced by Serum Binding Proteins and Depends on Protein Tyrosine Kinase Activation. Immunopharmacology 1999; 41: 21–29
   PubMedGoogle Scholar
• Van Molle W., Libert C., Fiers W., Brouckaert P. Alpha 1-Acid Glycoprotein and Alpha 1-Antitrypsin Inhibit TNF-Induced But Not Anti-Fas-Induced Apoptosis of Hepatocytes in Mice. J. Immunol. 1997; 159: 3555–3564
   PubMed Web of Science ®Google Scholar
• Libert C. Acute Phase Proteins as Protective Factors Against the Toxicity of Tumor Necrosis Factor. Verb. K. Acad. Geneeskd. Belg. 1997; 59: 515–523
   PubMedGoogle Scholar
• Philip A. G.S. White Blood Cells and Acute Phase Reactants in Neonatal Sepsis. Pediatrie 1984; 39: 371–378
   PubMedGoogle Scholar
• Friedman M. J., Blankenberg T., Sensabaugh G., Tenforde T. S. Recognition and Invasion of Human Erythrocytes by Malarial Parasites: Contribution of Sialoglycoproteins to Attachment and Host Specificity. J. Cell Biol. 1984; 98: 1672–1677
   PubMed Web of Science ®Google Scholar
• Gupta S. K., Oppenheim J. D., Glick J., Schulman S., Vanderberg J. P. Lack of Inhibitory Effects of Alpha 1-Acid Glycoprotein (Orosomucoid) on Plasmodium Falciparum Invasion of Human Erythrocytes. Am. J. Trop. Med. Hyg. 1985; 34: 841–846
   Web of Science ®Google Scholar
• Cheresh D. A., Haynes D. H., Distasio J. A. Interaction of an Acute Phase Reactant, Alpha 1-Acid Glycoprotein (Orosomucoid), with the Lymphoid Cell Surface: A Model for Non-specific Immune Suppression. Immunology 1984; 51: 541–548
   PubMed Web of Science ®Google Scholar
• Elg S. A., Mayer A. R., Carson L. F., Twiggs L. B., Hill R. B., Ramakrisnan S. Alpha 1-Acid Glycoprotein Is an Immunosuppressive Factor Found in Ascites from Ovarian Carcinoma. Cancer 1997; 80: 1448–1456
   PubMed Web of Science ®Google Scholar
• Shiyan S. D., Bovin N. V. Carbohydrate Composition and Immunomodulating Activity of Different Glycoforms of Alpha 1-Acid Glycoprotein. Glycoconjugate J. 1997; 14: 631–638
   PubMed Web of Science ®Google Scholar
• Bardos P., Luthier B., Avenet M., de Russe J., Muh J. P., Soutoul J. H., Weil J. D. Variations of the Concentrations of Certain Glycoproteins in Maternal Serum, Fetal Serum and Amniotic Fluid During Pregnancy. Clin. Chim. Acta 1976; 66: 353–363, (in French)
   PubMed Web of Science ®Google Scholar
• van Oss C. J., Gilmann C. F., Bronson P. M., Border J. R. Phagocytosis Inhibiting Properties of Human Serum Alpha-1-acid Glycoprotein. Immunol. Commun. 1974; 3: 321–328
   PubMed Web of Science ®Google Scholar
• Timoshenko A. V., Bovin N. V., Shiyan S. D., Vakhrushev S. Y., Andre S., Gabius H. J. Modification of the Functional Activity of Neutrophils Treated with Acute Phase Response Proteins. Biochemistry 1998; 63: 546–550
   PubMed Web of Science ®Google Scholar
• Costello M. J., Fiedel B. A., Gewurz H. Inhibition of Platelet Aggregation by Native and Desialised Alpha 1-Acid Glycoprotein. Nature (London) 1979; 281: 677–678
   PubMed Web of Science ®Google Scholar
• McNamara P. J., Jewell R. C., Gillespie M. N. The Interaction of Alpha 1-Acid Glycoprotein and Endogenous Autocoids, in Particular, Platelet Activating Factor. Prog. Clin. Biol. Res. 1989; 300: 307–319
   PubMedGoogle Scholar
• Thijs C. T., Groen A. K., Hovens M., Mok K. S. Risk of Gallstone Disease Is Associated with Serum Level of Alpha 1-Acid Glycoprotein. Epidemiology 1999; 10: 764–766
   PubMed Web of Science ®Google Scholar
• Gahmberg C. G., Andersson L. C. Membrane Glycoconjugates in the Maturation and Activation of T and B Lymphocytes. The Glycoconjugates, M. I. Horowitz, W. Pigman. 3, Academic Press, New York 1982; 231–264
   Google Scholar
• Stefanini G. F., Dirienzo W., Arnaud P., Nel A., Canonica G. W., Fudenberg H. H. Inhibitory Effect on an Antibody Against Alpha-1-acid Glycoprotein (Alpha-1-AGP) on Autologous Mixed Lymphocyte Reaction and Anti-T3 T-Lymphocyte Activation. Cell Immunol. 1986; 103: 65–72
   PubMed Web of Science ®Google Scholar
• Franzblau C., Schmid K., Faris B., Beldekas J., Garvin P., Kagan H. M., Baum B. J. The Interaction of Collagen with Alpha 1-Acid Glycoprotein. Biochim. Biophys. Acta 1976; 427: 302–314
   PubMed Web of Science ®Google Scholar
• Maeda H., Morinaga T., Mori I., Nishi K. Further Characterization of the Effects of Alpha-1-acid Glycoprotein on the Passage of Human Erythrocytes Through Micropores. Cell Struct. Funct. 1984; 9: 279–290
   PubMed Web of Science ®Google Scholar
• Neitchev V. Z., Kostova E., Goldenberg M., Doumanova L. Kinetics and Role of Alpha 1-Acid Glycoprotein-Dependent Osmotic Transport of Water and Ions in Palmitoyl-⌞-oleoyl Phosphatidylcholine Liposomes. Int. J. Biochem. Cell Biol. 1997; 29: 689–701
   PubMed Web of Science ®Google Scholar
• Staprans I., Felts J. M. The Effect of Alpha-1-acid Glycoprotein (Orosomucoid) on Triglyceride Metabolism in the Nephrotic Syndrome. Biochim. Biophys. Res. Commun. 1977; 79: 1272–1278
   PubMed Web of Science ®Google Scholar
• Maeda H., Murukami O., Kann M., Yamane J. The Growth-Stimulating Effect of Alpha-1-acid Glycoprotein in Cells in Culture. Proc. Soc. Exp. Biol. Med. 1980; 163: 223–227
   PubMed Web of Science ®Google Scholar
• Liu H. M., Brossmer R., Schmid K. Alpha 1-Acid Glycoprotein Promotes Nerve Growth In Vitro. Prog. Clin. Biol. Res. 1989; 300: 239–242
   PubMedGoogle Scholar
• Qin M., Öie S. Does Alpha 1-Acid Glycoprotein Act as a Non-factional Receptor for Alpha 1-Adrenergic Antagonists?. J. Pharm. Pharmacol. 1994; 46: 896–901
   PubMed Web of Science ®Google Scholar
• Sager G., Sandnes G. D., Aakesson J., Jacobsen S. Effect of Serum, Alpha-1 Acid Glycoprotein, Lipoproteins and Albumin on Human Mononuclear Leucocyte Beta-adrenoceptors. Acta Pharmacol. Toxicol. (Copenh.) 1986; 58: 193–203
   PubMedGoogle Scholar
• Zak-Nejmark T., Malolepszy J., Liebhart J., Liebhart E., Szeliga W. Histamine Binding Proteins Identified in Healthy Subjects and Asthmatic Patients. Arch. Immunol. Ther. Exp. (Warsz.) 1986; 34: 547–552
   PubMed Web of Science ®Google Scholar
• van Dijk W. Alpha 1-Acid Glycoprotein: A Naturally Occurring Anti-inflammatory Molecule?. Adv. Exp. Med. Biol. 1995; 376: 223–229
   PubMedGoogle Scholar
• Tilg H., Vannier E., Vachino G., Dinarello C. A., Mier J. W. Anti-inflammatory Properties of Hepatic Acute Phase Proteins: Preferential Induction of Interleukin 1 (IL-1) Receptor Antagonist over IL-1 Beta Synthesis by Human Peripheral Blood Mononuclear Cells. J. Exp. Med. 1993; 178: 1629–1636
   PubMed Web of Science ®Google Scholar
• Bourguignat A., Ferard G., Jenny J. Y., Gaudias J. Incomplete or Absent Acute Phase Response in Some Postoperative Patients. Clin. Chim. Acta 1997; 264: 27–35
   PubMed Web of Science ®Google Scholar
• Owens S. M., Mayersohn M., Woodworth J. R. Phencyclidine Blood Protein Binding: Influence of Protein, pH and Species. J. Pharmacol. Exp. Ther. 1983; 226: 656–660
   PubMed Web of Science ®Google Scholar
• Chauvelot-Moachon L., Marquis O., Giroud J.-P. Modification of Propranolol Binding to Alpha 1-Acid Glycoprotein by Serum Albumin. Biochem. Pharmacol. 1985; 34: 1591–1594
   PubMed Web of Science ®Google Scholar
• Shin W. G., Lee M. G., Lee M. H., Kim N. D. Factors Influencing the Protein Binding of Vancomycin. Biopharm. Drug Dispos. 1991; 12: 637–646
   PubMed Web of Science ®Google Scholar
• Parker R. B., Williams C. L., Laizure S. C., Lima J. J. Factors Affecting Serum Protein Binding of Cocaine in Humans. J. Pharmacol. Exp. Ther. 1995; 275: 605–610
   PubMed Web of Science ®Google Scholar
• Morin D., Simon N., Depres-Brummer P., Levi F., Tillement J.-P., Uriens S. Melatonin High-Affinity Binding to Alpha 1-Acid Glycoprotein in Human Serum. Pharmacology 1997; 54: 271–275
   PubMed Web of Science ®Google Scholar
• Krauss E. A., Polnaszek C. F., Scheeler D. A., Halsall H. B., Eckfeldt J. H., Holtzman J. L. Interaction Between Human Serum Albumin and Alpha 1-Acid Glycoprotein in the Binding of Lidocaine to Purified Fractions and Sera. J. Pharmacol. Exp. Ther. 1986; 239: 754–759
   PubMed Web of Science ®Google Scholar
• Schmid K., Binette J. P., Kamiyama S., Pfister V., Takahashi S. Studies on the Structure of Alpha 1-Acid Glycoprotein. II. Polymorphism of Alpha 1-Acid Glycoprotein and the Partial Resolution and Characterization of Its Variants. Biochemistry 1962; 1: 959–966
   Web of Science ®Google Scholar
• Schmid K., Tokita K., Yoshizaki H. The Alpha 1-Acid Glycoprotein Variants of Normal Caucasian and Japanese Individuals. J. Clin. Invest. 1965; 44: 1394–1401
   PubMed Web of Science ®Google Scholar
• Debray-Sachs M., Schmid K., Bixby E. M. The Polymorphic Forms of Alpha 1-Acid Glycoprotein of Mentally Retarded Patients. Ann. Biol. Clin (Paris) 1966; 24: 203–212, (in French)
   PubMedGoogle Scholar
• Tokita K., Burke J. F., Yoshizaki H., Fischer S., Schmid K. The Constancy of the Alpha 1-Acid Glycoprotein Variants of Normal Adults Under Condition of Severe Stress. J. Clin. Invest. 1966; 45: 1624–1630
   PubMed Web of Science ®Google Scholar
• Arnaud P., Gianazza E., Righetti P. G., Fundenberg H. H. The Role of Sialic Acid in the Microheterogeneity of Alpha 1-Acid Glycoprotein Study by Isoelectric Focusing and Titration Curves. Electrophoresis '79, B. J. Radola. Walter de Gruyter, Berlin 1980; 151–163
   Google Scholar
• Nicollet I., Lebreton J. P., Fontane M., Hiron M. Evidence for Alpha 1-Acid Glycoprotein Populations of Different PI Values After Concanavalin A Affinity Chromatography. Biochim. Biophys. Acta 1981; 668: 235–245
   PubMed Web of Science ®Google Scholar
• Altland K., Roeder T., Jakin H. M., Zimmer H. G., Neuhoff V. Demonstration of Alpha 1-Acid Glycoprotein (Orosomucoid) by Double One-Dimensional Slab Gel Electrophoresis: Evidence for Intra- and Interindividual Variability of the Microheterogeneity Pattern in Health and Disease. Clin. Chem. 1982; 28: 1000–1010
   PubMed Web of Science ®Google Scholar
• Elliott M. A., Elliott H. G., Gallagher K., McGuire J., Field M., Smith K. D. Investigation into the Concanavalin A Reactivity, Fucosylation and Oligosaccharide Microheterogeneity of Alpha 1-Acid Glycoprotein Expressed in Sera of Patients with Rheumatoid Arthritis. J. Chromatogr. B: Biomed. Sci. Appl. 1997; 688: 229–237
   PubMed Web of Science ®Google Scholar
• Herve F., Fouache F., Marche C., Tillement J.-P. Abnormal Microheterogeneity Detected in One Commercial Alpha 1-Acid Glycoprotein Preparation Using Chromatography on Immobilized Metal Affinity Adsorbent and on Hydroxyapatite. J. Chromatogr. B: Biomed. Sci. Appl. 1997; 688: 35–46
   PubMed Web of Science ®Google Scholar
• Sebetan I. M., Oshida S., Yuasa I., Tie J. Genetic Polymorphism of Orosomucoid ORM1 and ORM2 in Egyptians, Sudanese, and Qataris: Occurrence of Two New Alleles. Hum. Biol. 1997; 69: 121–129
   PubMed Web of Science ®Google Scholar
• Umetsu K., Yuasa I., Chen E.-R., Kudo T., Suzuki T. Orosomucoid 1 and Oro-somucoid 2 Types in the Taiwanese and Japanese: Evidence for Five New Orosomucoid Variants. Electrophoresis 1988; 9: 224–226
   PubMed Web of Science ®Google Scholar
• Herve F., Duche J. C., d'Athis P., Marche C., Barre J., Tillement J.-P. Binding of Disopyramide, Methadone, Dipyridamole, Chlorpromazine, Lignocaine and Progesterone to the Two Main Genetic Variants of Human Alpha 1-Acid Glycoprotein: Evidence for Drug Binding Differences Between the Variants and for the Presence of Two Separate Drug-Binding Sites on Alpha 1-Acid Glycoprotein. Pharmacogenetics 1996; 6: 403–415
   PubMedGoogle Scholar
• Dulmer M., Reker S., Nguyen T. T., Henke L., Henke J. Human Orosomucoid (ORM1) Subtyping: Further Population Genetic Data and Report on the Feasibility to Type Aged Blood and Stains. J. Forensic Sci. 1998; 43: 413–416
   PubMed Web of Science ®Google Scholar
• McCollam P. L., Crouch M. A., Arnaud P. Caucasian Versus African American Differences in Orosomucoid: Potential Implications for Therapy. Pharmacotherapy 1998; 18: 620–626
   PubMed Web of Science ®Google Scholar
• Moral P., Sandiumenge T., Vives S., Lutken N., Ortega F., Marrodan M. D., Fuster V. Human Genetic Variation in the Sierra de Gredos Mountain (Central Spain): Study of Several Polymorphisms. Ann. Hum. Biol. 1996; 23: 213–221
   PubMed Web of Science ®Google Scholar
• Duche J. C., Herve F., Tillement J.-P. Study of the Expression of the Genetic Variants of Human Alpha 1-Acid Glycoprotein in Healthy Subjects Using Isoelectric Focusing and Immunoblotting. J. Chromatogr. B: Biomed. Sci. Appl. 1998; 715: 103–109
   PubMedGoogle Scholar
• Herve F., Caron G., Duche J. C., Gaillard P., Abd Rahman N., Tsantili-Kakoulidou A., Carrupt P. A., d'Athis P., Tillement J.-P., Testa B. Ligand Specificity of the Genetic Variants of Human Alpha 1-Acid Glycoprotein: Generation of a Three-Dimensional Quantitative Structure–Activity Relationship Model for Drug Binding to the A Variant. Mol. Pharmacol. 1998; 54: 129–138
   PubMed Web of Science ®Google Scholar
• Johnson A. M., Schmid K., Alper C. A. Inheritance of Human Alpha 1-Acid Glycoprotein (Orosomucoid) Variants. J. Clin. Invest. 1969; 48: 2293–2299
   PubMed Web of Science ®Google Scholar
• Turyna B., Sarnecka-Keller M., Ciba T. Sugar Constituents of the Seromucoid in Insulin-Dependent Diabetes. Exp. Clin. Endocrinol. 1984; 83: 87–92
   PubMedGoogle Scholar
• Matei L. Plasma Proteins Glycosylation and Its Alteration in Disease. Rom. J. Intern. Med. 1997; 35: 3–11
   PubMedGoogle Scholar
• Kishino S., Nomura A., Di Z. S., Sugawara M., Iseki K., Kakinoki S., Kitabatake A., Miyazaki K. Changes in the Binding Capacity of Alpha 1-Acid Glycoprotein in Patients with Renal Insufficiency. Ther. Drug Monit. 1995; 17: 449–453
   PubMed Web of Science ®Google Scholar
• Ballou S. P., Lozanski F. B., Hodder S., Rzewnicki D. L., Mion L. C., Sipe J. D., Ford A. B., Kushner I. Quantitative and Qualitative Alternation of Acute-Phase Proteins in Healthy Elderly Persons. Age Ageing 1996; 25: 224–230
   PubMed Web of Science ®Google Scholar
• Raynes J. Variations in the Relative Proportions of Microheterogeneous Forms of Plasma Glycoproteins in Pregnancy and Disease. Biomedicine 1982; 36: 77–86
   Google Scholar
• Brinkman-Van der Linden C. M., Havenaar E. C., Van Ommen C. R., Van Kamp G. J., Gooren L. J., Van Dijk W. Oral Estrogen Treatment Induces a Decrease in Expression of Sialyl Lewis x on Alpha 1-Acid Glycoprotein in Females and Maleto-Female Transsexuals. Glycobiology 1996; 6: 407–412
   PubMed Web of Science ®Google Scholar
• Kishino S., Nomura A., Saitoh M., Sugawara M., Iseki K., Kitabatake A., Miyazaki K. Single-Step Isolation Method for Six Glycoforms of Human Alpha 1-Acid Glycoprotein by Hydroxylapatite Chromatography and Study of Their Binding Capacities for Disopyramide. J. Chromatogr. B:Biomed. Sci. Appl. 1997; 703: 1–6
   PubMedGoogle Scholar
• Winzler R. J. Glycoproteins in Disease. Glycoproteins of Blood Cells and Plasma, G. A. Jamieson, T. J. Greenwalt. Lippincott, New York 1971; 204–218
   Google Scholar
• Chio L. F., Oon C. J. Changes in Serum Alpha1-antitrypsin, Alpha1-acid Glycoprotein and Beta2 Glycoprotein in Patients with Malignant Hepatocellular Carcinoma. Cancer 1979; 43: 596–604
   PubMed Web of Science ®Google Scholar
• Hansen J. E., Larsen V. A., Bög-Hansen T. C. The Microheterogeneity of Alpha 1-Acid Glycoprotein in Inflammatory Lung Disease, Cancer of the Lung and Normal Health. Clin. Chim. Acta 1984; 138: 41–47
   PubMed Web of Science ®Google Scholar
• Fraeyman N. F., Dello C. D., Belpaire F. M. Alpha 1-Acid Glycoprotein Concentration and Molecular Heterogeneity: Relationship to Oxprenolol Binding in Serum from Healthy Volunteers and Patients with Lung Carcinoma or Cirrhosis. Br. J. Clin. Pharmacol. 1988; 25: 733–740
   PubMed Web of Science ®Google Scholar
• Herve F., Duche J. C., Jaurand M. C. Changes in the Expression and Microheterogeneity of the Genetic Variants of Human Alpha 1-Acid Glycoprotein in Malignant Mesothelioma. J. Chromatogr. B: Biomed. Sci. Appl. 1998; 715: 111–123
   PubMed Web of Science ®Google Scholar
• Duche J. C., Urien S., Simon N., Malaurie E., Monnet J., Barre J. Expression of the Genetic Variants of Human Alpha 1-acid Glycoprotein in Cancer. Clin. Biochem. 2000; 33: 197–202
   PubMed Web of Science ®Google Scholar
• Tinguely D., Baumann P., Conti M., Jonzier-Perey M., Schöpf J. Interindividual Differences in the Binding of Antidepressives to Plasma Proteins: The Role of the Variants of Alpha 1-Acid Glycoprotein. Eur. J. Clin. Pharmacol. 1985; 27: 661–666
   PubMed Web of Science ®Google Scholar
• Sluzewska A., Rybakowski J., Sobieska M., Wiktorowicz K. Concentration and Microheterogeneity Glycoforms of Alpha 1-Acid Glycoprotein in Major Depression. J. Affect. Disord. 1996; 39: 149–155
   PubMed Web of Science ®Google Scholar
• Sluzewska A., Sobieska M., Rybakowski J. Changes in Acute-Phase Proteins During Lithium Potentiation of Antidepressants in Refractory Depression. Neuropsychobiology 1997; 35: 123–127
   PubMed Web of Science ®Google Scholar
• Mackiewicz A., Marcinkowska-Pieta R., Ballou S., Mackiewicz S., Kushner I. Microheterogeneity of Alpha 1-Acid Glycoprotein in the Detection of Intercurrent Infection in Systemic Lupus Erythematosus. Arthritis Rheum. 1987; 30: 513–518
   PubMed Web of Science ®Google Scholar
• Brinkman-Van der Linden C. M., Van Ommen C. R., Van Dijk W. Glycosation of Alpha 1-Acid Glycoprotein in Septic Shock. Changes in Degree of Branching and in Expression of Sialyl Lewis(x) Groups. Glycoconj. J. 1996; 13: 27–31
   PubMed Web of Science ®Google Scholar
• Sobieska M., Fassbender K., Aeschlimann A., Bourgeois P., Mackiewicz S., Müller W. E. Still's Disease in Children and Adults: A Distinct Pattern of Acute-Phase Proteins. Clin. Rheumatol. 1998; 17: 258–260
   PubMed Web of Science ®Google Scholar
• Hrycaj P., Sobieska M., Mackiewicz S., Müller W. E. Microheterogeneity of Alpha 1-Acid Glycoprotein in Early and Established Rheumatoid Arthritis. J. Rheumatol. 1993; 20: 2020–2024
   PubMed Web of Science ®Google Scholar
• Lacki J. K., Klama K., Samborski W., Mackiewicz S. H., Müller W. E. Comparison of Microheterogeneity of Alpha 1-Acid Glycoprotein in Serum and Synovial Fluid from Rheumatoid Arthritis Patients. Clin. Rheumatol. 1994; 13: 598–604
   PubMed Web of Science ®Google Scholar
• Eap C. B., Fischer J. F., Baumann P. Variation in Relative Concentrations of Variants of Human Alpha 1-Acid Glycoprotein After Acute-Phase Conditions. Clin. Chim. Acta 1991; 203: 379–385
   PubMed Web of Science ®Google Scholar
• Schmeling A., Bockholdt B., Schroder H., Geserick G. Phenotype Change in Polymorphic Plasma Proteins Following Liver Transplantation. Exp. Clin. Immunogenet. 1986; 13: 78–83
   Google Scholar
• Lyngbye J., Kroll J. Quantitative Immunoelectrophoresis of Proteins in Serum from a Normal Population: Season, Age and Sex-Related Variations. Clin. Chem. 1971; 17: 495–500
   PubMed Web of Science ®Google Scholar
• Blain P. G., Mucklow J. C., Rawlins M. D., Roberts D. F., Routledge P. A., Shand D. G. Determinants of Plasma Alpha 1-Acid Glycoprotein Concentrations in Health. Br. J. Clin. Pharmacol. 1985; 20: 500–502
   PubMed Web of Science ®Google Scholar
• Israili Z. H., Bharmal F., Tiliakos N. Plasma levels of alpha 1-acid glycoprotein (AAG) in patients with rheumatoid arthritis (RA), and binding of nonsteroidal antiinflammatory drugs to AAG [abstract]. Fed. Proc. 1985; 44: 1124
   Google Scholar
• Yost R. L., DeVane C. L. Diurnal Variation of Alpha 1-Acid Glycoprotein Concentration in Normal Volunteers. J. Pharm. Sci. 1985; 74: 777–779
   PubMed Web of Science ®Google Scholar
• Bouvenat G., Bruguerolle B., Armaud C., Bartolin R. Absence of Changes in Elderly Patients of Circadian Variation of Various So-Called Inflammation Proteins. Ann. Biol. Clin. (Paris) 1989; 47: 76–78, (in French)
   PubMedGoogle Scholar
• Hashimoto S., Miwa M., Akasofu K., Nishida E. Changes in 40 Serum Proteins of Post-menopausal Women. Maturitas 1991; 13: 23–33
   PubMed Web of Science ®Google Scholar
• Wood M., Wood A. J.J. Changes in Plasma Drug Binding and Alpha1-acid Glycoprotein in Mother and Newborn Infant. Clin. Pharmacol. Ther. 1981; 29: 522–526
   PubMed Web of Science ®Google Scholar
• Feely J., Grimm T. A Comparison of Drug Protein Binding and Alpha 1-Acid Glycoprotein Concentration in Chinese and Caucasians. Br. J. Clin. Pharmacol. 1991; 31: 551–552
   PubMed Web of Science ®Google Scholar
• Hosseine S. J., Farid R., Ghalighi M. R., Feely J. Interethnic Differences in Drug Protein Binding and Alpha 1-Acid Glycoprotein Concentration. Ir. J. Med. Sci. 1995; 164: 26–27
   PubMed Web of Science ®Google Scholar
• Johnson J. A., Livingston T. N. Differences Between Blacks and Whites in Plasma Protein Binding of Drugs. Eur. J. Clin. Pharmacol. 1997; 51: 485–488
   PubMed Web of Science ®Google Scholar
• Jin E. Z. A Comparison of Alpha 1-Acid Glycoprotein Concentration and Disopyramide Binding in Chinese and Japanese. Hokkaido Igaku Zasshi 1999; 74: 279–288, (in Japanese)
   PubMedGoogle Scholar
• Lerman J., Strong H. A., LeDez K. M., Swartz J., Riedes M. J., Burrows F. A. Effects of Age on the Serum Concentration of Alpha 1-Acid Glycoprotein and the Binding of Lidocaine in Pediatric Patients. Clin. Pharmacol. Ther. 1989; 46: 219–225
   PubMed Web of Science ®Google Scholar
• Ganrot P. O. Variation of the Concentrations of Some Plasma Proteins in Normal Adults, in Pregnant Women and in Newborns Scand. J. Clin. Lab. Invest. 1972; 29(Suppl. 124)83–88
   Web of Science ®Google Scholar
• Petersen M. C., Moore R. G., Nation R. L., McMeniman W. Relationship Between the Transplacental Gradients of Bupivacaine and Alpha 1-Acid Glycoprotein. Br. J. Clin. Pharmacol. 1981; 12: 859–862
   PubMed Web of Science ®Google Scholar
• Nation R. L. Meperidine Binding in Maternal and Fetal Plasma. Clin. Pharmacol. Ther. 1981; 29: 472–479
   PubMed Web of Science ®Google Scholar
• Alt R., Erny P., Messer J., Willard D. Neonatal Bacterial Infections. Kinetic Study of C-Reactive Protein and Orosomucoid. Presse Med. 1984; 13: 1373–1376, (in French)
   PubMed Web of Science ®Google Scholar
• Pacifici G. M., Bianchetti G., Viani A., Rizzo G., Carrai M., Allen J., Morselli P. L. Plasma Protein Binding of Alpidem in Healthy Volunteers, in Neonates and in Liver or Renal Insufficiency. Eur. J. Clin. Pharmacol. 1989; 37: 29–32
   PubMed Web of Science ®Google Scholar
• Echizen H., Nakura M., Saotome T., Minoura S., Ishizaki T. Plasma Protein Binding of Disopyramide in Pregnant and Postpartum Women, and in Neonates and Their Mothers. Br. J. Clin. Pharmacol. 1990; 29: 423–430
   PubMed Web of Science ®Google Scholar
• Herngren L., Ehrnebo M., Boreus L. O. Drug Binding to Plasma Proteins During Human Pregnancy and in the Perinatal Period. Studies on Cloxacillin and Alprenolol. Dev. Pharmacol. Ther. 1983; 6: 110–124
   PubMedGoogle Scholar
• Notarianni L. J. Plasma Protein Binding of Drugs in Pregnancy and in Neonates. Clin. Pharmacokinet. 1990; 18: 20–36
   PubMed Web of Science ®Google Scholar
• Booker P. D., Taylor C., Saba G. Perioperative Changes in Alpha 1-Acid Glycoprotein Concentrations in Infants Undergoing Major Surgery. Br. J. Anaesth. 1996; 76: 365–368, Comments in Br. J. Anaesth. 1996, 77, 130
   PubMed Web of Science ®Google Scholar
• Larsson B. A., Lonnqvist P. A., Olsson G. L. Plasma Concentrations of Bupivacaine in Neonates After Continuous Epidural Infusion. Anesth. Analg. 1997; 84: 501–505
   PubMed Web of Science ®Google Scholar
• Mazoit J. X., Denson D. D., Samii K. Pharmacokinetics of Bupivacaine Following Caudal Anesthesia in Infants. Anesthesiology 1988; 68: 387–391
   PubMed Web of Science ®Google Scholar
• Meistelman C., Benhamou D., Barre J., Levron J. C., Mehe V., Mazoit X., Ecoffey C. Effects of Age on Plasma Protein Binding of Sufentanil. Anesthesiology 1990; 72: 470–473
   PubMed Web of Science ®Google Scholar
• Freer D. E., Statland B. E., Johnson M., Felton H. Reference Values for Selected Enzyme Activities and Protein Concentrations in Serum and Plasma Derived from Cord-Blood Specimens. Clin. Chem. 1979; 25: 565–569
   PubMed Web of Science ®Google Scholar
• Piafsky K. M., Woolner E. A. The Binding of Basic Drugs to Alpha 1-Acid Glycoprotein in Cord Serum. J. Pediatr. 1982; 100: 820–822
   PubMed Web of Science ®Google Scholar
• Verbeeck R. K., Cardinal J. A., Wallace S. M. Effect of Age and Sex on the Plasma Binding of Acidic and Basic Drugs. Eur. J. Clin. Pharmacol. 1984; 27: 91–97
   PubMed Web of Science ®Google Scholar
• Lalonde R. L., Tenero D. M., Burlew B. S., Herring V. L., Bottorff M. B. Effects of Age on the Protein Binding and Disposition of Propranolol Stereoisomers. Clin. Pharmacol. Ther. 1990; 47: 447–455
   PubMed Web of Science ®Google Scholar
• Israili Z. H., Unpublished results
   Google Scholar
• Eap C. B., Cuendet C., Baumann P. Binding of d-Methadone, l-Methadone, and dl-Methadone to Proteins in Plasma of Healthy Volunteers: Role of the Variants of Alpha1-acid Glycoprotein. Clin. Pharmacol. Ther. 1990; 47: 338–346
   PubMed Web of Science ®Google Scholar
• Paxton J. W., Briant R. H. Alpha 1-Acid Glycoprotein Concentrations and Propranolol Binding in Elderly Patients with Acute Illness. Br. J. Clin. Pharmacol. 1984; 18: 806–810
   PubMed Web of Science ®Google Scholar
• Mennens G., Meuldermans W., Snoeck E., Heykants J. Plasma Protein Binding of Risperidone and Its Distribution in Blood. Psychopharmacology (Berlin) 1994; 114: 566–572
   PubMed Web of Science ®Google Scholar
• Colangelo P., Chandler M., Blouin R., McNamara P. Stereoselective Binding of Propranolol in the Elderly. Br. J. Clin. Pharmacol. 1989; 27: 519–522
   PubMed Web of Science ®Google Scholar
• Veering B. T., Burm A. G., Souverijn J. H., Seree J. M., Spierdijk J. The Effect of Age on Serum Concentration of Albumin and Alpha 1-Acid Glycoprotein. Br. J. Clin. Pharmacol. 1990; 29: 201–206
   PubMed Web of Science ®Google Scholar
• Parish R. C., Spivey C. Influence of Menstrual Cycle Phase on Serum Concentrations of Alpha 1-Acid Glycoprotein. Br. J. Clin. Pharmacol. 1991; 31: 197–199
   PubMed Web of Science ®Google Scholar
• Tuck C. H., Holleran S., Berglund L. Hormonal Regulation of Lipoprotein(a) Levels: Effects of Estrogen Replacement Therapy on Lipoprotein(a) and Acute Phase Reactants in Postmenopausal Women. Atheroscler. Thromb. Vasc. Biol. 1997; 17: 1822–1829
   PubMed Web of Science ®Google Scholar
• Denson D. D., Coyle D. E., Thompson G. A., Santos D., Turner P. A., Myers J. A., Knapp R. Bupivacaine Protein Binding in the Term Parturient: Effects of Lactic Acidosis. Clin. Pharmacol. Ther. 1984; 35: 702–709
   PubMed Web of Science ®Google Scholar
• Bardy A. H., Hiilesmaa V. K., Teramo K., Neuvonen P. J. Protein Binding of Antiepileptic Drugs During Pregnancy, Labor, and Puerperium. Ther. Drug. Monit. 1990; 12: 40–46
   PubMed Web of Science ®Google Scholar
• Kvasnicka J., Marek J., Zivny J., Calda P., Umlaufova A., Markova M., Pecen L. Changes in Levels of Cell Adhesion Molecules, Acute Phase Proteins, Lipids and Hemostasis in Relation to Levels of Endogenous Estrogens During Pregnancy and After Ovariectomy. Ceska Gynekol. 1997; 62: 332–337, (in Czechoslavakian)
   PubMedGoogle Scholar
• Krauer B., Dayer P., Anner R. Changes in Serum Albumin and Alpha 1-Acid Glycoprotein Concentrations During Pregnancy: An Analysis of Fetal–Maternal-Pairs. Br. J. Obstet. Gynecol. 1984; 91: 875–881
   PubMedGoogle Scholar
• Wulf H., Munstedt P., Maier C. Plasma Protein Binding of Bupivacaine in Pregnant Women at Term. Acta Anaesthesiol. Scand. 1991; 35: 129–133
   PubMed Web of Science ®Google Scholar
• Ohman E. M., Teo K. K., Johnson A. H., Collins P. B., Dowsett D. G., Ennis J. T., Horgan J. H. Abnormal Cardiac Enzyme Responses After Strenuous Exercise: Alternative Diagnostic Aids. Br. Med. J. 1982; 285: 1523–1526
   PubMed Web of Science ®Google Scholar
• Kapil R. P., Axelson J. E., Mansfield I. L., Edwards D. J., McErlane B., Mason M. A., Lalka D., Kerr C. R. Disopyramide Pharmacokinetics and Metabolism: Effect of Inducers. Br. J. Clin. Pharmacol. 1987; 24: 781–791
   PubMed Web of Science ®Google Scholar
• Benedek I. H., Blouin R. A., McNamara P. J. Influence of Smoking on Serum Protein Composition and the Protein Binding of Drugs. J. Pharm. Pharmacol. 1984; 36: 214–216
   PubMed Web of Science ®Google Scholar
• Ahlsten G., Tuvemo T., Gebre-Medhin M. Selected Trace Elements and Proteins in Serum of Apparently Healthy Newborn Infants of Mothers Who Smoked During Pregnancy. Acta Paediatr. Scand. 1989; 78: 671–676
   PubMed Web of Science ®Google Scholar
• Shima M., Adachi M. Effects of Environmental Tobacco Smoke on Serum Levels of Acute Phase Proteins in Schoolchildren. Prev. Med. 1996; 25: 617–624
   PubMed Web of Science ®Google Scholar
• Shirao K., Kusano C., Natsugoe S., Yoshinaka H., Fukumoto T., Aiko T., Shimazu H. Postoperative Changes in Acute Phase Proteins in Patients with Esophageal Cancer. Nippon Geka Gakkai Zashi 1992; 93: 675–683, (in Japanese)
   PubMedGoogle Scholar
• Holley F. O., Ponganis K. V., Stanski D. R. Effects of Cardiac Surgery with Cardiopulmonary Bypass on Lidocaine Disposition. Clin. Pharmacol. Ther. 1984; 35: 617–626
   PubMed Web of Science ®Google Scholar
• Mori T., Sasaki J., Kawaguchi H., Handa K., Takada Y., Matsunaga A., Kono S., Arakawa K. Serum Glycoproteins and Severity of Coronary Artherosclerosis. Am. Heart J. 1995; 129: 234–238
   PubMed Web of Science ®Google Scholar
• Kjeldsen J., Schaffalitzky de Muckadell O. B., Junker P. Seromarkers of Collagen I and III Metabolism in Active Crohn's Disease: Relation to Response to Therapy. Gut 1995; 37: 805–810
   PubMed Web of Science ®Google Scholar
• Kjeldsen J., Lauritsen K., Schaffalitzky de Muckadell O. B. Disease Activity and Serum Concentrations of Orosomucoid: Improved Decision-Making for Tapering Prednisolone Therapy in Patients with Active Inflammatory Bowel Disease. Scan. J. Gastroenterol. 1997; 32: 933–941
   PubMed Web of Science ®Google Scholar
• Silamut K., Molunto P., Ho M., Davis T. M., White N. J. Alpha 1-Acid Glycoprotein (Orosomucoid) and Plasma Protein Binding of Quinine in Falciparum Malaria. Br. J. Clin. Pharmacol. 1991; 32: 311–315
   PubMed Web of Science ®Google Scholar
• Maes M., Delange J., Ranjan R., Meltzer H. Y., Desnyder R., Cooremans W., Scharpe S. Acute Phase Proteins in Schizophrenia, Mania and Major Depression: Modulation by Psychotropic Drugs. Psychiatry Res. 1997; 66: 1–11
   PubMed Web of Science ®Google Scholar
• Lacki J. K., Klama K., Samborski W., Mackiewicz S. H., Mackiewicz U., Muller W. Acute Phase Response in Rheumatoid Arthritis Patients Treated with Immunosuppressive Drugs. Materia Medica Polona 1995; 27: 47–51
   PubMedGoogle Scholar
• Oon C. J., Yo S. L., Chio L. F., Chua D., Tan Y. D. The Evaluation of Tumor Marker Proteins in the Diagnosis of Primary Hepatocellular Carcinoma. Ann. Acad. Med. Singapore 1980; 9: 228–233
   PubMedGoogle Scholar
• Chu C. Y.-T., Lai L. T.-Y., Polaka H. P. Value of Plasma Alpha-1-Acid Glycoprotein Assay in the Detection of Human Colorectal Cancer: Comparison with Carcinoembryonic Antigen. J. Natl. Cancer Inst. 1982; 68: 75–79
   PubMed Web of Science ®Google Scholar
• Trautner K., Cooper E. H., Haworth S., Ward A. M. An Evaluation of Serum Protein Profiles in the Long Term Surveillance of Prostatic Cancer Scand. J. Urol. Nephrol. 1980; 14: 143–149
   Google Scholar
• Yuceyar S., Erturk S., Dirican A., Cengiz A., Saner H. The Role of Acute-Phase Reactant Proteins, Carcinoembryonic Antigen and CA 19–9 as a Marker in the Preoperative Staging of Colorectal Cancer: A Prospective Clinical Study. Int. Surg. 1996; 81: 136–139
   PubMed Web of Science ®Google Scholar
• Roberts J. G., Keyser J. W., Baum M. Serum Alpha 1-Acid Glycoprotein as an Index of Dissemination in Breast Cancer. Br. J. Surg. 1975; 62: 816–819
   PubMed Web of Science ®Google Scholar
• Fish R. G., Yap A. K., James K. Changes in Serum Acute Phase Proteins in Breast Cancer Patients Receiving Methotrexate Infusion Therapy. Clin. Biochem. 1982; 15: 4–8
   PubMed Web of Science ®Google Scholar
• Onizuka K., Migita S., Yamada H., Matsumoto I. Serum Protein Fractions in Patients with Laryngeal Cancer Undergoing Radiation Therapy. Possibility as a Prognostic Factor. Fukuoka Igaku Zasshi 1999; 90: 46–58, (in Japanese)
   PubMedGoogle Scholar
• Fish R. G., Gill T. S., Adams M., Kerby I. Serum Haptoglobin and Alpha 1-Acid Glycoprotein as Indicators of the Effectiveness of cis-Diamminedichloroplatinum (CDDP) in Ovarian Cancer Patients—A Preliminary Report. Eur. J. Cancer Clin. Oncol. 1984; 20: 625–630
   PubMedGoogle Scholar
• Ganz P. A., Ma P. Y., Wang H. J., Elshoff R. M. Evaluation of Three Biochemical Markers for Serially Monitoring the Therapy of Small-Cell Lung Cancer. J. Clin. Oncol. 1987; 5: 472–479
   PubMed Web of Science ®Google Scholar
• Laurell C.-B., Rannevik G. A Comparison of Plasma Protein Changes Induced by Danazol, Pregnancy and Estrogens. J. Clin. Endocrinol. Metab. 1979; 49: 719–725
   PubMed Web of Science ®Google Scholar
• Cushman M., Meilahn E. N., Psaty B. M., Kuller L. H., Dobs A. S., Tracy R. P. Hormone Replacement Therapy, Inflammation and Hemstasisin Elderly Women. Arterioscler. Thromb. Vasc. Biol. 1999; 19: 893–899
   PubMed Web of Science ®Google Scholar
• Briggs M. H., Briggs M. Effect of Oral Ethinylestradiol on Serum Proteins in Normal Women. Contraception 1971; 3: 381–387
   Web of Science ®Google Scholar
• Walle U. K., Fagan T. C., Topmiller M. J., Conradi E. C., Walle T. The Influence of Gender and Sex Steroid Hormones on the Plasma Binding of Propranolol. Br. J. Clin. Pharmacol. 1994; 37: 21–25
   PubMed Web of Science ®Google Scholar
• Fex G., Adielsson G., Mattson W. Oestrogen-like Effects of Tamoxifen on the Concentration of Proteins in Plasma. Acta Endocrinol. (Copenh.) 1981; 97: 109–113
   PubMedGoogle Scholar
• Chen X., Xiao B. Effect of Once Weekly Administration of Mifepristone on Ovarian Function in Normal Women. Contraception 1997; 56: 175–180
   PubMed Web of Science ®Google Scholar
• Morita K., Yamaji A. Changes in the Concentration of Alpha 1-Acid Glycoprotein in Epileptic Patients. Eur. J. Clin. Pharmacol. 1994; 46: 137–142
   PubMed Web of Science ®Google Scholar
• Tiula E., Neuvonen P. J. Antiepileptic Drugs and Alpha 1-Acid Glycoprotein [Letter]. N. Engl. J. Med. 1982; 307: 1148
   PubMedGoogle Scholar
• Hans P., Brichant J. F., Pieron F., Pieyns P., Born J. D., Lany M. Elevated Plasma Alpha 1-Acid Glycoprotein Levels—Lack of Connection to Resistance to Vercuronium Blockade Induced by Anticonvulsant Therapy. J. Neurosurg. Anesthesiol. 1997; 9: 3–7
   PubMed Web of Science ®Google Scholar
• Rapeport W. G., Brodie M. J. Lack of Effect of Carbamazepine on Serum Alpha-1-Acid Glycoprotein Concentration. Clin. Chem. 1985; 31: 1253
   PubMed Web of Science ®Google Scholar
• Bruguerolle B., Jadot G., Bussiere H. Together, Phenobarbital and Carbamazepine Lower the Alpha 1-Acid Glycoprotein Concentration in Plasma of Epileptic Patients [Letter]. Clin. Chem. 1984; 30: 590–591
   PubMed Web of Science ®Google Scholar
• Parish R. C., Gotz V. P., Lopez L. M., Mehta J. L., Curry S. H. Serum Lidocaine Concentrations Following Application to the Oropharynx: Effects of Cimetidine. Ther. Drug Monit. 1987; 9: 292–297
   PubMed Web of Science ®Google Scholar
• Parish R. C., Gotz V. P., Mehta J. L. Cimetidine Does Not Increase Alpha 1-Acid Glycoprotein Serum Concentrations. Br. J. Clin. Pharmacol. 1988; 25: 514–517
   PubMed Web of Science ®Google Scholar
• Vannice J. L., Taylor J. M., Ringold G. M. Glucocorticoid-Mediated Induction of Alpha 1-Acid Glycoprotein: Evidence for Hormone-Regulated RNA Processing. Proc. Natl. Acad. Sci. USA 1984; 81: 4241–4245
   PubMed Web of Science ®Google Scholar
• Barbosa J., Seal U. S., Doe R. P. Effects of Anabolic Steroids on Haptoglobin, Orosomucoid, Plasminogen, Fibrinogen, Transferrin, Ceruloplasmin, Alpha 1-Antitrypsin, Beta-glucuronidase and Total Serum Proteins. J. Clin. Endocrinol. Metab. 1971; 33: 388–398
   PubMed Web of Science ®Google Scholar
• Marsden J. R., Shuster S., Dennis J. D. Antipyrine, Clearance and Alpha-1-acid Glycoprotein Levels After Isotretinoin. Hum. Toxicol. 1985; 4: 335–338
   PubMedGoogle Scholar
• Reuss F., Schley J., Muller-Oerlinghausen B. The Relation Between Serum Concentration of Alpha 1-Acid Glycoprotein and Clinical Characteristics of Patients Treated with Perazine. Pharmacopsychiatry 1985; 18: 145–146
   Web of Science ®Google Scholar
• Baumann P., Tinguely D., Schöpf J. Increase of Alpha-1-acid Glycoprotein After Treatment with Amitriptyline. Br. J. Clin. Pharmacol. 1982; 14: 102–103
   PubMed Web of Science ®Google Scholar
• Feely J., Clee M., Pereira L., Guy E. Enzyme Induction with Rifampicin: Lipoproteins and Drug Binding to Alpha 1-Acid Glycoprotein. Br. J. Clin. Pharmacol. 1983; 16: 195–197
   PubMed Web of Science ®Google Scholar
• Müller W. E., Stillbauer A. E., El-Gamal S. Psychotropic Drug Competition for [3H]-Imipramine Binding Further Indicates the Presence of Only One High-Affinity Drug Binding Site on Human Alpha 1-Acid Glycoprotein. J. Pharm. Pharmacol. 1983; 35: 684–686
   PubMed Web of Science ®Google Scholar
• Müller W. E. Drug Binding Sites on Human Alpha 1-Acid Glycoprotein. Prog. Clin. Biol. Res. 1989; 300: 363–378
   PubMedGoogle Scholar
• El-Gamal S., Wollert U., Müller W. E. Binding of Several Phenothiazine Neuroleptics to a Common Binding Site of Alpha 1-Acid Glycoprotein, Orosomucoid. J. Pharm. Sci. 1983; 72: 202–205
   PubMed Web of Science ®Google Scholar
• Verbeeck R. K., Cardinal J. A., Hill A. G., Midha K. K. Binding of Phenothiazine Neuroleptics to Plasma Proteins. Biochem. Pharmacol. 1983; 32: 2565–2570
   PubMed Web of Science ®Google Scholar
• Goolkasian D. L., Slaughter R. L., Edwards D. J., Lalka D. Displacement of Lidocaine from Serum Alpha 1-Acid Glycoprotein Binding Sites by Basic Drugs. Eur. J. Clin. Pharmacol. 1983; 25: 413–417
   PubMed Web of Science ®Google Scholar
• Maruyama T., Furuie M. A., Hibino S., Otagiri M. Comparative Study of Interaction Mode of Diazepines with Human Serum Albumin and Alpha 1-Acid Glycoprotein. J. Pharm. Sci. 1992; 81: 16–20
   PubMed Web of Science ®Google Scholar
• Miyoshi T., Sukimoto K., Otagiri M. Investigation of the Interaction Mode of Phenothiazine Neuroleptics with Alpha 1-Acid Glycoprotein. J. Pharm. Pharmacol. 1992; 44: 28–33
   PubMed Web of Science ®Google Scholar
• Kaliszan R., Nasal A., Turowski M. Binding Site for Basic Drugs on Alpha 1-Acid Glycoprotein as Revealed by Chemometric Analysis of Biochromatographic Data. Biomed. Chromatogr. 1995; 9: 211–215
   PubMed Web of Science ®Google Scholar
• Urien S., Albengres E., Zini R., Tillement J.-P. Evidence for Binding of Certain Acidic Drugs to Alpha 1-Acid Glycoprotein. Biochem. Pharmacol. 1982; 31: 3687–3689
   PubMed Web of Science ®Google Scholar
• Essassi D., Zini R., Tillement J.-P. Use of 1-Anilino-8-naphthalene Sulfonate as a Fluorescent Probe in the Investigation of Drug Interactions with Human Alpha-1-acid Glycoprotein and Serum Albumin. J. Pharm. Sci. 1990; 79: 9–13
   PubMed Web of Science ®Google Scholar
• Maruyama T., Otagiri M., Takadate A. Characterization of Drug Binding Sites on Alpha 1-Acid Glycoprotein. Chem. Pharm. Bull. (Tokyo) 1990; 38: 1688–1691
   PubMed Web of Science ®Google Scholar
• Kerkay J., Westphal U. Steroid–Protein Interaction XIX. Complex Formation Between Alpha 1-Acid Glycoprotein and Steroid Hormones. Biochem. Biophys. Acta 1968; 170: 324–333
   PubMed Web of Science ®Google Scholar
• Brinkschulte M., Breyer-Pfaff U. The Contribution of Alpha 1-Acid Glycoprotein, Lipoproteins, and Albumin to the Plasma Binding of Perazine, Amitriptyline, and Nortriptyline in Healthy Man. Naunyn Schmiedeberg's Arch. Pharmacol. 1980; 314: 61–66
   Google Scholar
• Shami M. R., Skellern G. G., Whiting B. Binding of [3H]Mianserin to Bovine Serum Albumin, Human Serum Albumin and Alpha 1-Acid Glycoprotein. J. Pharm. Pharmacol. 1984; 36: 16–20
   PubMed Web of Science ®Google Scholar
• Ferry D. G., Caplan N. B., Cubeddu L. X. Interaction Between Antidepressants and Alpha 1-Adrenergic Receptor Antagonists on the Binding to Alpha 1-Acid Glycoprotein. J. Pharm. Sci. 1986; 75: 146–149
   PubMed Web of Science ®Google Scholar
• Wallace S. M., Halsall H. B. Photoaffinity Labelling of the Progesterone Binding Site in Human Orosomucoid. Biophys. J. 1983; 41: 408a
   Web of Science ®Google Scholar
• Schmid K., Chen L. H., Occhino J. C., Foster J. A., Sperandio K. Topography of Human Alpha 1-Acid Glycoprotein. Biochemistry 1976; 15: 2245–2254
   PubMed Web of Science ®Google Scholar
• Lemaire M., Tillement J.-P. The Binding Characteristics of Some Adrenergic Beta-Receptor Antagonists to Human Serum Proteins. Biochem. Pharmacol. 1982; 31: 359–365
   PubMed Web of Science ®Google Scholar
• Chassany O., Urien S., Claudepierre P., Bastian G., Tillement J.-P. Comparative Serum Protein Binding of Anthracycline Derivatives. Cancer Chemother. Pharmacol. 1996; 38: 571–573
   PubMed Web of Science ®Google Scholar
• Nasal A., Radwanska A., Osmialowski K., Bucinski A., Kaliszan R., Barker G. E., Sun P., Hartwick R. A. Quantitative Relationship Between the Structure of Beta-adrenolytic and Antihistaminic Drugs and Their Retention on an Alpha 1-Acid Glycoprotein Column. Biomed. Chromatogr. 1994; 8: 125–129
   PubMed Web of Science ®Google Scholar
• Meuldermans W. E., Hurkmans R. M., Heykants J. J. Plasma Protein Binding and Distribution of Fentanyl, Sufentanil, Alfentanil and Lofentanil in Blood. Arch. Int. Pharmacodyn. Ther. 1982; 257: 4–19
   PubMedGoogle Scholar
• Drayer D. E. Clinical Consequences of the Lipophilicity and Plama Protein Binding of Antiarrhythmic Drugs and Active Metabolites. Ann. NY Acad. Sci. 1984; 432: 45–56
   PubMed Web of Science ®Google Scholar
• Herve F., Gomas E., Duche J. C., Tillement J.-P. Evidence for Differences in the Binding of Drugs to the Two Main Genetic Variants of Human Alpha 1-Acid Glycoprotein. Br. J. Clin. Pharmacol. 1993; 36: 241–249
   PubMed Web of Science ®Google Scholar
• Baumann P., Eap C. B. Contribution of the Variants of Alpha 1-Acid Glycoprotein to Its Binding of Drugs. Prog. Clin. Biol. Res. 1989; 300: 379–397
   PubMedGoogle Scholar
• Jolliet-Riant P., Boukef M. F., Duche J. C., Simon N., Tillement J.-P. A Genetic Variant A of Human Alpha 1-Acid Glycoprotein Limits the Blood Brain Transfer of Drugs It Binds. Life Sci. 1998; 62: PL219–PL26
   PubMed Web of Science ®Google Scholar
• Hanada K., Obta T., Hirai M., Arai M., Ogata H. Enantiomeric Binding of Propranolol, Disopyramide, and Verapamil to Human Alpha(1)-acid Glycoprotein. J. Pharm. Sci. 1989; 89: 751–757
   Google Scholar
• Quaglia M. G., Bossu E., Dell'Aquila C., Guidotti M. Determination of the Binding of a Beta 2-Blocker Drug, Frusemide and Ceftriaxone to Serum Proteins by Capillary Zone Electrophoresis. J. Pharm. Biomed. Anal. 1997; 15: 1033–1039
   PubMed Web of Science ®Google Scholar
• McDonnell P. A., Caldwell G. W., Masucci J. A. Using Capillary Electrophoresis/Frontal Analysis to Screen Drugs Interacting with Human Serum Proteins. Electrophoresis 1998; 19: 448–454
   PubMed Web of Science ®Google Scholar
• Amini A., Westerlund D. Evaluation of Association Constants Between Drug Enantiomers and Human Alpha 1-Acid Glycoprotein by Applying a Partial-Filling Technique in Affinity Capillary Electrophoresis. Anal. Chem. 1998; 70: 1425–1430
   PubMed Web of Science ®Google Scholar
• Reijenga J. C., Gaykema A., Mikkers F. E. Determination of Theophylline Binding to Human Serum Proteins by Isotachophoresis. J. Chromatogr. 1984; 287: 365–370
   PubMed Web of Science ®Google Scholar
• Rodrigues Rosas M. E., Shibukawa A., Ueda K., Nakagawa T. Enantiomeric Protein Binding of Semotiadil and Levosemotiadil Determined by High-Performance Frontal Analysis. J. Pharm. Biomed. Anal. 1997; 15: 1595–1601
   PubMed Web of Science ®Google Scholar
• Rodrigues Rosas M. E., Shibukawa A., Yoshikawa Y., Kuroda Y., Nakagawa T. Binding Study of Semotiadil and Levosemotiadil with Alpha(1)-acid Glycoprotein Using High-Performance Frontal Analysis. Anal. Biochem. 1999; 274: 27–33
   PubMed Web of Science ®Google Scholar
• Oravcova J., Sojkova D., Lindner W. Comparison of the Hummel– Dreyer Method in High-Performance Liquid Chromatography and Capillary Electrophoresis Conditions for the Study of the Interaction of (RS)-, (R)-, and (S)-Carvedilol with Isolated Plasma Proteins. J. Chromatogr. B: Biomed. Appl. 1996; 682: 349–357
   PubMedGoogle Scholar
• Wright D. S., Friedman M. L., Jenkins S. H., Heineman W. R., Halsall H. B. Sequestration Electrochemistry: The Interaction of Chlorpromazine and Human Orosomucoid. Anal. Biochem. 1988; 171: 290–293
   PubMed Web of Science ®Google Scholar
• Otagiri M., Yamamichi R., Maruyama T., Imai T., Suenaga A., Imamura Y., Kimachi K. Drug Binding to Alpha 1-Acid Glycoprotein Studied by Circular Dichroism. Pharm. Res. 1989; 6: 156–159
   PubMed Web of Science ®Google Scholar
• Defaye G., Basset M., Chambaz E. M. Electron Spin Resonance Study of Human Alpha 1-Acid Glycoprotein Interaction with a Spin Labelled Steroid. Chem. Biol. Interact. 1979; 28: 323–331
   PubMed Web of Science ®Google Scholar
• Forstell-Karlsson A., Remaeus A., Roos H., Andersson K., Borg P., Hamalainen M., Karlsson R. Biosensor Analysis of the Interaction Between Immobilized Human Serum Albumin and Drug Compounds for Prediction of Human Serum Albumin Binding Levels. J. Med. Chem. 2000; 43: 1986–1992
   PubMed Web of Science ®Google Scholar
• Schuhmacher J., Buhner K., Witt-Laido A. Determination of the Free Fraction of Drugs Strongly Bound to Plasma Proteins. J. Pharm. Sci. 2000; 89: 1008–1021
   PubMed Web of Science ®Google Scholar
• Chellani M. Isothermal Titration Calorimetry: Biological Applications. Am. Biotechnol. Lab. 1999; 17: 14–18
   Google Scholar
• Wring S. A., Harmon K. A., Bruner J., Polli J. W., Serabjit-Singh C. Automated Plasma Protein Screen: Rapid, Robust and Timely for Drug Discovery. Drug Metab. Rev. 2000; 32(Suppl. 2)179
   Google Scholar
• Morse D. S., Abernethy D. R., Greenblatt D. J. Methodological Factors Influencing Plasma Binding of Alpha 1-Acid Glycoprotein-bound and Albumin-Bound Drugs. Int. J. Clin. Pharmacol. Ther. Toxicol. 1985; 23: 535–539
   PubMedGoogle Scholar
• Behm H. L., Wagner J. G. Errors in Interpretation of Data from Equilibrium Dialysis Protein Binding Experiments. Res. Commun. Chem. Pathol. Pharmacol. 1979; 26: 145–159
   PubMedGoogle Scholar
• Pike E., Skuterud B., Kierulf P., Fremstad D., Abdel Sayed S. M., Lunde P. K.M. Binding and Displacement of Basic and Neutral Drugs in Normal and Orosomucoid-Deficient Plasma. Clin. Pharmacokinet. 1981; 6: 367–374
   PubMed Web of Science ®Google Scholar
• Urien S., Albengres E., Pinquier J.-L., Tillement J.-P. Role of Alpha 1-Acid Glycoprotein, Albumin, and Non-esterified Fatty Acids in Serum Binding of Apazone and Warfarin. Clin. Pharmacol. Ther. 1986; 39: 683–689
   PubMed Web of Science ®Google Scholar
• Sager G., Jaeger R., Little C. Binding of Prazosin to Alpha 1-Acid Glycoprotein and Albumin: Effect of Protein Purity and Concentrations. Pharmacol. Toxicol. 1989; 64: 365–368
   PubMedGoogle Scholar
• Dayton P. G., Stiller R. L., Cook D. R., Perel J. M. The Binding of Ketamine to Plasma Proteins: Emphasis on Human Plasma. Eur. J. Clin. Pharmacol. 1983; 24: 825–831
   PubMed Web of Science ®Google Scholar
• Kennedy E., Frischer H. Distribution of Primaquine in Human Blood: Drug-Binding to Alpha 1-Glycoprotein. J. Lab. Clin. Med. 1990; 116: 871–878
   PubMedGoogle Scholar
• Sager G., Little C. The Effect of the Plasticizers TBEP (Tris-(2-butoxyethyl)-phosphate) and DEHP (Di-(2-ethylhexyl)-phthalate) on Beta-adrenergic Ligand Binding to Alpha 1-Acid Glycoprotein and Mononuclear Leukocytes. Biochem. Pharmacol. 1989; 38: 2551–2557
   PubMed Web of Science ®Google Scholar
• Nyberg G., Mårtensson E. Binding of Thioridazine and Thioridazine Metabolites to Serum Proteins. An In Vitro Study. Naunyn Schmiedeberg's Arch. Pharmacol. 1982; 319: 189–196
   PubMed Web of Science ®Google Scholar
• Kerkay J., Westphal U. Steroid–Protein Interaction. XXI. Metal Ion Inhibition of Association Between Progesterone and Alpha 1-Acid Glycoprotein. Arch. Biochem. Biophys. 1969; 129: 480–489
   PubMed Web of Science ®Google Scholar
• Kopitar V. Z., Weisenberger H. Specific Binding of Dipyridamole on Human Serum Protein. Isolation, Identification, and Characterization as Alpha 1-Acid Glycoprotein. Arzneim. Forsch. (Drug Res.) 1971; 21: 859–862, (in German)
   PubMed Web of Science ®Google Scholar
• Dale O., Nilsen O. G. Differences in the Serum Protein Binding of Prazosin in Man and Rat. Biochem. Pharmacol. 1984; 33: 1719–1724
   PubMed Web of Science ®Google Scholar
• Milhaly G. W., Ching M. S., Klejn M. B., Paull J., Smallwood R. A. Differences in the Binding of Quinine and Quinidine to Plasma Proteins. Br. J. Clin. Pharmacol. 1987; 24: 769–774
   PubMed Web of Science ®Google Scholar
• Wanwimolruk S., Edwards G., Ward S. R., Breckenridge A. M. The Binding of the Antimalarial Arteether to Human Plasma Proteins In Vitro. J. Pharm. Pharmacol. 1992; 44: 940–942
   PubMed Web of Science ®Google Scholar
• Israili Z. H., El-Attar H. Binding of Some Acidic Drugs to Alpha 1-Acid Glycoprotein [Abstract]. Clin. Pharmacol. Ther. 1983; 33: 255
   Web of Science ®Google Scholar
• Zini R., Morin D. M., Jouenne P., Tillement J.-P. Cicletanine Binding to Human Plasma Proteins and Erythrocytes: A Particular HSA–Drug Interaction. Life Sci. 1988; 43: 2103–2115
   PubMed Web of Science ®Google Scholar
• Barre J., Didey F., Urien S., Riant P., Tillement J.-P. In Vitro Studies on the Blood Distribution of Almitrine. Pharmacology 1989; 38: 381–387
   PubMed Web of Science ®Google Scholar
• Leow K. P., Wright A. W., Cramond T., Smith M. T. Determination of the Serum Protein Binding of Oxycodone and Morphine Using Ultrafiltration. Ther. Drug Monit. 1993; 15: 440–447
   PubMed Web of Science ®Google Scholar
• Rudy A. C., Poynor W. J. Binding of Pyrimethamine to Human Plasma Proteins and Erythrocytes. Pharm. Res. 1990; 7: 1055–1060
   PubMed Web of Science ®Google Scholar
• Urien S., Morin D., d'Athis P., Coulomb B., Tillement J.-P. Serum Binding of Indapamide in Health and Disease: Primary Role of Alpha 1-Acid Glycoprotein. J. Clin. Pharmacol. 1988; 28: 458–462
   PubMed Web of Science ®Google Scholar
• Urien S., Guez D., Thenot A., Tillement J.-P. Indapamide Binding to Alpha 1-Acid Glycoprotein: Consequences on Its Blood Distribution and Plasma Binding in Disease States. Prog. Clin. Biol. Res. 1989; 300: 449–452
   PubMedGoogle Scholar
• Fitos I., Visy J., Simonyi M., Hermansson J. Stereoselective Distribution of Acenocoumarol Enantiomers in Human Plasma: Chiral Chromatographic Analysis of the Filtrate. Chirality 1993; 5: 346–349
   PubMed Web of Science ®Google Scholar
• Mazoit J. X., Cao L. S., Samii K. Binding of Bupivacaine to Human Serum Proteins: Isolated Albumin and Isolated Alpha 1-Acid Glycoprotein. Differences Between the Two Enantiomers Are Partly due to Cooperativity. J. Pharmacol. Exp. Ther. 1996; 276: 109–115
   PubMed Web of Science ®Google Scholar
• Ofori-Adjei D., Ericsson Ö., Lindström B., Sjöqvist F. Protein Binding of Chloroquine Enantiomers and Desethylchloroquine. Br. J. Clin. Pharmacol. 1986; 22: 356–358
   PubMed Web of Science ®Google Scholar
• Hiep B. T., Gimenez F., Khanh V. V., Hung N. K., Thuillier A., Farrinotti R., Fernandez C. Binding of Chlorpheniramine Enantiomers to Human Plasma Proteins. Chirality 1999; 11: 501–504
   PubMed Web of Science ®Google Scholar
• Lima J. J., Jungbluth G. L., Devine G. L., Robertson L. W. Stereoselective Binding of Disopyramide to Human Plasma Proteins. Life Sci. 1984; 35: 835–839
   PubMed Web of Science ®Google Scholar
• Gross A. S., Eser C., Kus G. M., Eichelbaum M. Enantioselective Gallopamil Protein Binding. Chirality 1993; 5: 414–418
   PubMed Web of Science ®Google Scholar
• Brocks D. R., Skeith K. J., Johnston C., Emamibafrani J., Davis P., Russell A. S., Jamali F. Hematologic Disposition of Hydroxychloroquine Enantiomers. J. Clin. Pharmacol. 1994; 34: 1088–1097
   PubMed Web of Science ®Google Scholar
• McLachlan A. J., Cutler D. J., Tett S. E. Plasma Protein Binding of the Enantiomers of Hydroxychloroquine and Metabolites. Eur. J. Clin. Pharmacol. 1993; 44: 481–484
   PubMed Web of Science ®Google Scholar
• Oravcova J., Sojkova D., Bencsikova E., Bohov P., Trnovec T. Stereoselective Binding of Isradipine to Human Plasma Proteins. Chirality 1995; 7: 167–172
   PubMed Web of Science ®Google Scholar
• Romach M. K., Piafsky K. M., Abel J. G., Khouw V., Sellers E. M. Methadone Binding to Orosomucoid (Alpha1-acid Glycoprotein): Determinant of Free Fraction in Plasma. Clin. Pharmacol. Ther. 1981; 29: 211–217
   PubMed Web of Science ®Google Scholar
• Oravcova J., Lindner W., Szalay P., Bohacik L., Trnovec T. Interaction of Propafenone Enantiomers with Human Alpha 1-Acid Glycoprotein. Chirality 1991; 3: 30–34
   PubMed Web of Science ®Google Scholar
• Walle U. K., Walle T., Bai S. A., Olanoff L. S. Stereoselective Binding of Propranolol to Human Plasma, Alpha1-acid Glycoprotein and Albumin. Clin. Pharmacol. Ther. 1983; 34: 718–723
   PubMed Web of Science ®Google Scholar
• Albani F., Riva R., Contin M., Baruzzi A. Stereoselective Binding of Propranolol Enantiomers to Human Alpha 1-Acid Glycoprotein and Human Plasma. Br. J. Clin. Pharmacol. 1984; 18: 244–246
   PubMed Web of Science ®Google Scholar
• Belpaire F. M., Wynant P., Van Trappen P., Dhont M., Verstraete A., Bogaert M. G. Protein Binding of Propranolol and Verapamil Enantiomers in Maternal and Fetal Serum. Br. J. Clin. Pharmacol. 1995; 39: 190–193
   PubMed Web of Science ®Google Scholar
• Brunner F., Müller W. E. The Stereoselectivity of the “Single Drug Binding Site” of Human Alpha 1-Acid Glycoprotein (Orosomucoid). J. Pharm. Pharmacol. 1987; 39: 986–990
   PubMed Web of Science ®Google Scholar
• Bastian G., Urien S., Bree F., Rocher P., Crambes O., Tillement J.-P. Stereoselective Binding of Tertatolol and 4-Hydroxytertatolol to Human Plasma Proteins. Eur J. Drug Pharmacokinet. 1992; 17: 233–236
   PubMed Web of Science ®Google Scholar
• Gross A. S., Heuer B., Eichelbaum M. Stereoselective Protein Binding of Verapamil Enantiomers. Biochem. Pharmacol. 1998; 37: 4623–4627
   Google Scholar
• Fitos I., Visy J., Simonyi M. Binding of Vinca Alkaloid Analogues to Human Serum Albumin and to Alpha 1-Acid Glycoprotein. Biochem. Pharmacol. 1991; 41: 377–383
   PubMed Web of Science ®Google Scholar
• Fernandez C., Gimenez F., Thuillier A., Farrinotti R. Stereoselective Binding of Zopiclone to Human Plasma Proteins. Chirality 1999; 11: 129–132
   PubMed Web of Science ®Google Scholar
• Bonde J., Jensen N. M., Burgaard P., Angelo H. R., Graudal N., Kampmann J. P., Pedersen L. E. Displacement of Lidocaine from Human Proteins by Disopyramide. Pharmacol. Toxicol. 1987; 60: 151–155
   PubMedGoogle Scholar
• Hartrick C. T., Dirkes W. E., Coyle D. E., Raj P. P., Denson D. D. Influence of Bupivacaine on Mepivacaine Protein Binding. Clin. Pharmacol. Ther. 1984; 36: 546–550
   PubMed Web of Science ®Google Scholar
• Belpaire F. M., Braeckman R. A., Bogaert M. G. Binding of Oxprenolol and Propranolol to Serum, Albumin and Alpha 1-Acid Glycoprotein in Man and Other Species. Biochem. Pharmacol. 1984; 33: 2065–2069
   PubMed Web of Science ®Google Scholar
• Meijer D. K., van der Sluijs P. Binding of Drugs to Alpha 1-Acid Glycoprotein and Its Desialylated Form. Influence on Hepatic Disposition and Implications for Drug Targeting to the Liver. Prog. Clin. Biol. Res. 1989; 300: 143–167
   PubMedGoogle Scholar
• Bree F., Houin G., Barre J., Riant P., Tillement J.-P. Binding to Alpha 1-Acid Glycoprotein and Relevant Apparent Volume of Distribution. Prog. Clin. Biol. Res. 1989; 300: 321–336
   PubMedGoogle Scholar
• Gesink-van der Veer B. J., Burm A. G., Vletter A. A., Bovill J. G. Influence of Crohn's Disease on the Pharmacokinetics and Pharmacodynamics of Alfentanil. Br. J. Anaesth. 1993; 71: 827–834
   PubMed Web of Science ®Google Scholar
• Piafsky K. M., Borgå O., Odar-Cederlöf I., Johansson C., Sjöqvist F. Increased Plasma Protein Binding of Propranolol and Chlorpromazine Mediated by Disease-Induced Elevations of Plasma Alpha1-acid Glycoprotein. N. Engl. J. Med. 1978; 299: 1435–1439
   PubMed Web of Science ®Google Scholar
• Echizen H., Saima S., Umeda N., Ishizaki T. Altered Protein Binding of Disopyramide in Plasma from Patients with Cancer and with Inflammatory Diseases. Ther. Drug Monit. 1987; 9: 272–278
   PubMed Web of Science ®Google Scholar
• Bruguerolle B., Philip-Joet F., Armaud C., Armaud A. Consequences of Inflammatory Processes on Lignocaine Protein Binding During Anesthesia in Fibre Bronchoscopy. Br. J. Clin. Pharmacol. 1985; 20: 180–181
   PubMed Web of Science ®Google Scholar
• Morin D., Zini R., Ledewyn S., Colonna J. P., Czajka M., Tillement J.-P. Binedaline Binding to Plasma Proteins and Red Blood Cells in Humans. J. Pharm. Sci. 1985; 74: 727–730
   PubMed Web of Science ®Google Scholar
• Tonn G. R., Kerr C. R., Axelson J. E. In Vitro Binding of Propafenone and 5-Hydroxypropafenone in Serum, in Solutions of Isolated Serum Proteins, and to Red Blood Cells. J. Pharm. Sci. 1992; 81: 1098–1103
   PubMed Web of Science ®Google Scholar
• Pibouin M., Zini R., Nguyen P., Renouard A., Tillement J.-P. Binding of 8-Methoxypsoralen to Human Serum Proteins and Red Blood Cells. Br. J. Dermatol. 1987; 117: 207–215
   PubMed Web of Science ®Google Scholar
• Hamberger C., Barre J., Brandebourger M., Urien S., Taiclet A., Thenot J. P., Tillement J.-P. Progabide and SL 75102 Binding to Plasma Proteins and Red Blood Cells in Humans. Int. J. Clin. Pharmacol. Ther. Toxicol. 1987; 25: 178–184
   PubMed Web of Science ®Google Scholar
• Barchowsky A., Shand D. G., Stargel W. W., Wagner G. S., Routledge P. A. On the Role of Alpha1-acid Glycoprotein in Lignocaine Accumulation Following Myocardial Infarction. Br. J. Clin. Pharmacol. 1982; 13: 411–415
   PubMed Web of Science ®Google Scholar
• Schneider R. E., Bishop H., Kendall M. J., Quarterman C. P. Effect of Inflammatory Disease on Plasma Concentrations of Three Beta-adrenoceptor Blocking Agents. Int. J. Clin. Pharmacol. Ther. Toxicol. 1981; 19: 158–162
   PubMedGoogle Scholar
• Huang J. D., Öie S. Influence of Serum Protein Binding on Hepatic Clearance of S-Disopyramide in the Rabbit. J. Pharm. Pharmacol. 1985; 37: 471–475
   PubMed Web of Science ®Google Scholar
• Tatman A. J., Wrigley S. R., Jones R. M. Resistance to Atracurium in a Patient with an Increase in Plasma Alpha 1 Globulins. Br. J. Anaesth. 1991; 67: 623–625, Comments: Br. J. Anaesth. 1992, 69, 111.
   PubMed Web of Science ®Google Scholar
• Kays M. B., White R. L., Gatti G., Gambertoglio J. G. Ex Vivo Protein Binding of Clindamycin in Sera with Normal and Elevated Alpha 1-Acid Glycoprotein Concentrations. Pharmacotherapy 1992; 12: 50–55
   PubMed Web of Science ®Google Scholar
• Niewiarowski S., Lukasiewicz H., Nath N., Tai Sha A. Inhibition of Human Platelet Aggregation by Dipyridamole and Two Related Compounds and Its Modi-fication by Acid Glycoproteins of Human Plasma. J. Lab. Clin. Med. 1975; 86: 64–76
   PubMedGoogle Scholar
• Arredondo G., Calvo R., Marcos F., Martinez-Jorda R., Suarez E. Protein Binding of Itraconazole and Fluconazole in Patients with Cancer. Int. J. Clin. Pharmacol. Ther. 1995; 33: 449–452
   PubMed Web of Science ®Google Scholar
• Aguirre C., Troconiz I. F., Valdivieso A., Jimenez R. M., Gonzalez J. P., Calvo R., Rodriguez-Sasiain J. M. Pharmacokinetics and Pharmacodynamics of Penbutolol in Healthy and Cancer Subjects: Role of Altered Protein Binding. Res. Commun. Mol. Pathol. Pharmacol. 1996; 92: 53–72
   PubMed Web of Science ®Google Scholar
• Abramson F. P., Jenkins J., Ostchega Y. Effects of Cancer and Its Treatments on Plasma Concentration of Alpha1-acid Glycoprotein and Propranolol Binding. Clin. Pharmacol. Ther. 1982; 32: 659–663
   PubMed Web of Science ®Google Scholar
• Garfinkel D., Mamelok R. D., Blaschke T. F. Altered Therapeutic Range for Quinidine After Myocardial Infarction and Cardiac Surgery. Ann. Intern. Med. 1987; 107: 48–50
   PubMed Web of Science ®Google Scholar
• Brown J. E., Shand D. G. Therapeutic Drug Monitoring of Antiarrhythmic Agents. Clin. Pharmacokinet. 1982; 7: 125–148
   PubMed Web of Science ®Google Scholar
• Arredondo G., Martinez-Jorda R., Calvo R., Aguirre C., Suarez E. Protein Binding of Itraconazole and Fluconazole in Patients with Chronic Renal Failure. Int. J. Clin. Pharmacol. Ther. 1994; 32: 361–364
   PubMed Web of Science ®Google Scholar
• Schneider R. E., Babb J., Bishop H., Mitchard A. M., Hawkins C. F. Plasma Levels of Propranolol in Treated Patients with Coeliac Disease and Patients with Crohn's Disease. Br. Med. J. 1976; 2: 794–795
   PubMed Web of Science ®Google Scholar
• Aguirre C., Calvo R., Rodriguez-Sasiain J. M. Serum Protein Binding of Penbutolol in Patients with Hepatic Cirrhosis. Int. J. Clin. Pharmacol. Ther. Toxicol. 1988; 26: 566–569
   PubMedGoogle Scholar
• Bower S., Sear J. W., Roy R. C., Carter R. F. Effects of Different Hepatic Pathologies on Disposition of Alfentanil in Anaesthetized Patients. Br. J. Anaesth. 1992; 68: 462–465
   PubMed Web of Science ®Google Scholar
• Edwards D. J., Axelson J. E., Slaughter R. L., Elvin A. T., Lalka D. Factors Affecting Quinidine Protein Binding in Man. Clin. Pharmacokinet. 1984; 9: 96–97
   Web of Science ®Google Scholar
• Nyberg G., Mårtensson E. Determination of Free Fractions of Tricyclic Antidepressants. Naunyn Schmiedeberg's Arch. Pharmacol. 1984; 327: 260–265
   Web of Science ®Google Scholar
• Rutledge D. R., Chong M.-T., Nelson M. V. Interspecies Differences in the Effect of pH on Gallopamil Protein Binding to Albumin and Alpha 1-Acid Glycoprotein. Eur. J. Clin. Pharmacol. 1991; 40: 603–607
   PubMed Web of Science ®Google Scholar
• Pruitt A. W., Dayton P. G. A Comparison of the Binding of Drugs to Adult and Cord Plasma. Eur. J. Clin. Pharmacol. 1971; 4: 59–62
   PubMed Web of Science ®Google Scholar
• Martinez Jorda R., Aguirre C., Calvo R., Rodriguez-Sasiain J. M., Erill S. Decrease in Penbutolol Central Response as a Cause of Changes in Its Serum Protein Binding. J. Pharm. Pharmacol. 1990; 42: 164–166
   PubMed Web of Science ®Google Scholar
• Essassi D., Urien S., Zini R., Tillement J.-P. Pipequaline Transport from Blood to Brain and Liver: Role of Plasma Protein-Bound Drug. J. Pharm. Pharmacol. 1989; 41: 595–600
   PubMed Web of Science ®Google Scholar
• Giles H. G., Corrigall W. A., Khouw V., Sellers E. M. Plasma Protein Binding of Phencyclidine. Clin. Pharmacol. Ther. 1982; 31: 77–82
   PubMed Web of Science ®Google Scholar
• Sukiyama R., Partridge W. M. Orosomucoid-Bound Propranolol Is Available for Transport Through the Blood-Brain Barrier [Abstract]. Clin Res. 1981; 29: A278
   Google Scholar
• Curtin N. J., Newell D. R., Harris A. L. Modulation of Dipyridamole Action by Alpha 1-Acid Glycoprotein. Reduced Potentiation of Quinazoline Antifolate (CB3717) Cytotoxicity by Dipyridamole. Biochem. Pharmacol. 1989; 38: 3281–3288
   PubMed Web of Science ®Google Scholar
• Wood D. M., Ford J. M., Roberts C. J. Variability in the Plasma Protein Binding of Velnacrine (1-Hydroxy Tacrine Hydrochloride). A Potential Agent for Alzheimer's Disease. Eur. J. Clin. Pharmacol. 1996; 50: 115–119
   PubMed Web of Science ®Google Scholar
• Shastri R. A., Barre J., Houin G., Hamberger C., Tillement J.-P. Binding of Bornaprolol to Human Serum Proteins and Blood Cells. Int. J. Clin. Pharmacol. Ther. Toxicol. 1986; 24: 351–356
   PubMedGoogle Scholar
• Barber M. D., Ross J. A., Preston T., Shenkin A., Fearon K. C. Fish Oil-Enriched Nutritional Supplement Attenuates Progression of the Acute-Phase Response in Weight-Losing Patients with Advanced Pancreatic Cancer. J. Nutr. 1999; 129: 1120–1125
   PubMed Web of Science ®Google Scholar
• Torres I., Suarez E., Rodriguez-Sasiain J. M., Aguirre C., Calvo R. Differential Effect of Cancer on the Serum Protein Binding to Mianserin and Imipramine. Eur. J. Drug Metab. Pharmacokinet. 1995; 20: 107–111
   PubMed Web of Science ®Google Scholar
• Pejovic M., Djordjevic V., Ignjatovic I., Stamenic T., Stefanovic V. Serum Levels of Some Acute Phase Proteins in Kidney and Urinary Tract Urothelial Cancers. Int. Urol. Nephrol. 1997; 29: 427–432
   PubMedGoogle Scholar
• Calvo R., Jimenez R. M., Troconiz I. F., Suarez E., Gonzalo A., Lucero M. L., Rackza E., Orjales A. Serum Protein Binding of Lerisetron, a Novel Specific 5HT3 Antagonist, in Patients with Cancer. Cancer Chemother. Pharmacol. 1998; 42: 418–422
   PubMed Web of Science ®Google Scholar
• Szilvas A., Szekely G., Kremmer T., Boldizsar M., Blazovics A., Feher J. Serum Acid Alpha-1-glycoprotein (AGP) Levels in Gastrointestinal Tumors. Orv. Hetil. 1998; 139: 2199–2202, (in Hungarian)
   PubMedGoogle Scholar
• Weiss J. F., Morantz R. A., Bradley W. P., Chretien P. B. Serum Acute-Phase Proteins and Immunoglobulins in Patients with Gliomas. Cancer Res. 1979; 39: 542–544
   PubMed Web of Science ®Google Scholar
• Johansson B. G., Kindmark C. O., Trell E. Y., Wollheim F. A. Sequential Changes of Plasma Proteins After Myocardial Infarction Scand. J. Clin. Lab. Invest. 1971; 29(Suppl. 124)117–126
   Google Scholar
• Routledge P. A., Barchowsky A., Bjornsson T. D., Kitchell B. B., Shand D. G. Lidocaine Plasma Protein Binding. Clin. Pharmacol. Ther. 1980; 27: 347–351
   PubMed Web of Science ®Google Scholar
• Freilich D. I., Giardina E.-G. V. Imipramine Binding to Alpha-1-acid Glycoprotein in Normal Subjects and Cardiac Patients. Clin. Pharmacol. Ther. 1984; 35: 670–674
   PubMed Web of Science ®Google Scholar
• Caplin J. L., Johnston A., Hamer J., Camm A. J. The Acute Changes in Serum Binding of Disopyramide and Flecainamide After Myocardial Infarction. Eur. J. Clin. Pharmacol. 1985; 28: 253–255
   PubMed Web of Science ®Google Scholar
• Thomson A. H., Kelman A. W., de Vane P. J., Hillis W. S., Whiting B. Changes in Lignocaine Disposition During Long-Term Infusion in Patients with Acute Ventricular Arrhythmias. Ther. Drug Monit. 1987; 9: 283–291
   PubMed Web of Science ®Google Scholar
• Held C., Hjemdahl P., Rehnqvist N., Wallen N. H., Forslund L., Bjorkander I., Angelin B., Wiman B. Haemostatic Markers, Inflammatory Parameters and Lipids in Male and Female Patients in the Angina Prognosis Study in Stockholm (APSIS). A Comparison with Healthy Controls. J. Intern. Med. 1997; 241: 59–69
   PubMed Web of Science ®Google Scholar
• Fiotti N., Giansante C., Ponte E., Delbello C., Calabrese S., Zacchi T., Dobrina A., Guarnieri G. Atherosclerosis and Inflammation. Patterns of Cytokine Regulation in Patients with Peripheral Arterial Disease. Atherosclerosis 1999; 145: 51–60
   PubMed Web of Science ®Google Scholar
• Paxton J. W., Norris R. M. Propranolol Disposition After Acute Myocardial Infarction. Clin. Pharmacol. Ther. 1984; 36: 337–342
   PubMed Web of Science ®Google Scholar
• Burrows F. A., Lerman J., LeDez K. M., Strong H. A. Alpha 1-Acid Glycoprotein and the Binding of Lidocaine in Children with Congenital Heart Disease. Can. J. Anaesth. 1990; 37: 883–888
   PubMed Web of Science ®Google Scholar
• Chu J. S., Kishino S., Nomura A., Miyazaki K. Serum Alpha-1-Acid Glycoprotein, Sialic Acid, and Protein Binding of Disopyramide in Normal Subjects and Cardiac Patients. Chung Kaio Yao Li Hsueh Pao 1997; 18: 408–410
   PubMed Web of Science ®Google Scholar
• Nieto E., Vieta E., Alvarez L., Torra M., Colon F., Gasto C. Alpha-1-acid Glycoprotein in Major Depressive Disorders. Relationship to Severity, Response to Treatment, and Imipramine Plasma Levels. J. Affect. Disord. 2000; 59: 159–164
   PubMed Web of Science ®Google Scholar
• Nemeroff C. B., Krishnan K. R., Blazer D. G., Knight D. L., Benjamin D., Meyerson L. R. Elevated Plasma Concentrations of Alpha 1-Acid Glycoprotein, a Putative Endogenous Inhibitor of the Tritiated Imipramine Binding Site, in Depressed Patients. Arch. Gen. Psychiatry. 1990; 47: 337–340
   PubMed Web of Science ®Google Scholar
• Healy D., Calvin J., Whitehouse A. M., White W., Wilton-Cox H., Theodorou A. E., Lawrence K. M., Horton R. W., Paykel E. S. Alpha-1-acid Glycoprotein in Major Depressive and Eating Disorders. J. Affect. Disord. 1991; 22: 13–20
   PubMed Web of Science ®Google Scholar
• Stoff D. M., Ieni J., Friedman E., Bridger W. H., Pollock L., Vitiello B. Platelet3H-Imipramine Binding, Serotonin Uptake, and Plasma Alpha 1-Acid Glycoprotein in Disruptive Behavior Disorders. Biol. Psychiatry 1991; 29: 494–498
   PubMed Web of Science ®Google Scholar
• Maes M., Scharpe S., Bosmans E., Vandewoude M., Suy E., Uyttenbroeck W., Cooreman W., Vandervosrt C., Raus J. Disturbances in Acute Phase Plasma Protein During Melancholia: Additional Evidence for the Presence of an Inflammatory Process During That Illness. Prog. Neuropsychopharmacol. Biol. Psychiatry 1992; 16: 501–515
   PubMed Web of Science ®Google Scholar
• Hornig M., Goodman D. B., Kamoun K., Amsterdam J. D. Positive and Negative Acute Phase Proteins in Affective Subtypes. J. Affect. Disord. 1998; 49: 9–18
   PubMed Web of Science ®Google Scholar
• Calil H. M., Jostell K. G., Cowdry R. W., Potter W. Z. Zimelidine and Norzimelidine Protein Binding Measured by Equilibrium Dialysis and Cerebrospinal Fluid. Clin. Pharmacol. Ther. 1982; 31: 522–527
   PubMed Web of Science ®Google Scholar
• Ilzecka J., Dobosz B. Acute Phase Proteins: Alpha 1-Acid Glycoprotein (AGP) and Alpha 1-Antitrypsin (ACT) in Serum of Patients with Cerebral Ischemic Stroke. Neurol. Neurochir. Pol. 1998; 32: 495–502, (in Polish)
   PubMedGoogle Scholar
• Contin M., Riva R., Albani F., Perucca, Lamontanara G., Baruzzi A. Alpha 1-Acid Glycoprotein Concentration and Serum Protein Binding of Carbamazepine and Carbamazepine-10,11 Epoxide in Children with Epilepsy. Eur. J. Clin. Pharmacol. 1985; 29: 211–214
   PubMed Web of Science ®Google Scholar
• Takaishi M., Sadamoto K., Takami S., Ishioka S., Hozawa S., Yamakido M. Changes in Serum Protein Levels Between Acute and Convalescent Phases in Patients with Respiratory Infections. Jpn. J. Thoracic Dis. 1990; 28: 315–319, (in Japanese)
   Google Scholar
• Morita K., Yamaji A. Changes in the Serum Protein Binding of Vancomycin in Patients with Methicillin-Resistant Staphylococcus aureus Infection: The Role of Serum Alpha 1-Acid Glycoprotein Levels. Ther. Drug Monit. 1995; 17: 107–112
   PubMed Web of Science ®Google Scholar
• Öie S., Jacobson M. A., Abrams D. I. Alpha 1-Acid Glycoprotein Levels in AIDS Patients Before and After Short-Term Treatment with Zidovudine (Zdv) [Letter]. J. Acquir. Immun. Defic. Syndr. 1993; 5: 531–533
   Google Scholar
• Mansor S. M., Molyneux M. E., Taylor T. E., Ward S. A., Wirima J. J., Edwards G. Effect of Plasmodium falciparum Malaria Infection on the Plasma Concentration of Alpha 1-Acid Glycoprotein and the Binding of Quinine in Malawian Children. Br. J. Clin. Pharmacol. 1991; 32: 317–321
   PubMed Web of Science ®Google Scholar
• Wanwimolruk S., Denton J. R. Plasma Protein Binding of Quinine: Binding to Human Serum Albumin, Alpha 1-Acid Glycoprotein, and Plasma from Patients with Malaria. J. Pharm. Pharmacol. 1992; 44: 806–811
   PubMed Web of Science ®Google Scholar
• Cenni B., Meyer J., Brandt R., Betschart B. The Antimalarial Drug Halofantrine Is Bound Mainly to Low and High Density Lipoproteins in Human Serum. Br. J. Clin. Pharmacol. 1995; 39: 519–526
   PubMed Web of Science ®Google Scholar
• Paradowski M., Lobos M., Kuydowicz J., Krakowiak M., Kubasiewicz-Ujma B. Acute Phase Proteins in Serum and Cerebrospinal Fluid in the Course of Bacterial Meningitis. Clin. Biochem. 1995; 28: 459–466
   PubMed Web of Science ®Google Scholar
• Chambers R. E., Stross P., Barry R. E., Whicher J. T. Serum Amyloid A Protein Compared with C-Reactive Protein, Alpha 1-Antitrypsin and Alpha 1-Acid Glycoprotein as a Monitor of Inflammatory Bowel Disease. Eur. J. Clin. Invest. 1987; 17: 460–467
   PubMed Web of Science ®Google Scholar
• Holmquist L., Ahren C., Fallstrom S. P. Relationship Between Results of Laboratory Tests and Inflammatory Activity Assessed by Colonoscopy in Children and Adolescents with Ulcerative Colitis and Crohn's Colitis. J. Paediatr. Gastroenterol. Nutr. 1989; 9: 187–193
   PubMed Web of Science ®Google Scholar
• Lacki J. K., Samborski W., Mackiewicz S. H. Interleukin-10 and Interleukin-6 in Lupus Erythematosus and Rheumatoid Arthritis. Correlations with Acute Phase Proteins. Clin. Rheumatol. 1997; 16: 275–278, 1995, 233–242
   PubMed Web of Science ®Google Scholar
• Teirlynck O., Belpaire F. M., Andreasen F. Binding of Aprindine and Moxaprindine to Human Serum, Alpha 1-Acid Glycoprotein and Serum of Healthy and Diseased Humans. Eur. J. Clin. Pharmacol. 1982; 21: 427–431
   PubMed Web of Science ®Google Scholar
• Belpaire F. M., Bogaert M. G., Rosseneu M. Binding of Beta-adrenoceptor Blocking Drugs to Human Serum Albumin, to Alpha1-Acid Glycoprotein and to Human Serum. Eur. J. Clin. Pharmacol. 1982; 22: 253–256
   PubMed Web of Science ®Google Scholar
• Bloedow D. C., Hansbrough J. F., Hardin T. C., Simons M. A. Postburn Serum Drug Binding and Serum Protein Concentrations. J. Clin. Pharmacol. 1986; 26: 147–151
   PubMed Web of Science ®Google Scholar
• Macfie A. G., Magides A. D., Reilly C. S. Disposition of Alfentanil in Burn Patients. Br. J. Anaesth. 1992; 69: 447–450
   PubMed Web of Science ®Google Scholar
• Jungbluth G. L., Pasko M. T., Jusko W. J. Factors Affecting Ceftriaxone Plasma Protein Binding During Open Heart Surgery. J. Pharm. Sci. 1989; 78: 807–811
   PubMed Web of Science ®Google Scholar
• Venkataraman R., Habucky K., Burckart G. J., Ptachcinski R. J. Clinical Pharmacokinetics in Organ Transplant Patients. Clin. Pharmacokinet. 1989; 16: 134–161
   PubMed Web of Science ®Google Scholar
• Boosalis M. G., Gray D., Walker S., Sutliff S., Talwalker R., Mazumder A. The Acute Phase Response in Autologous Bone Marrow Transplantation. J. Med. 1992; 23: 175–193
   PubMedGoogle Scholar
• Haughey D. B., Kraft C. J. Disopyramide Protein Binding and Alpha 1-Acid Glyco-protein Concentrations in Serum Obtained from Kidney Transplant Recipients. Clin. Pharmacokinet. 1984; 9: 97–98
   Web of Science ®Google Scholar
• Kroboth P. D., Smith R. B., Sorkin M. I., Silver M. R., Rault R., Garry M., Juhl R. P. Triazolam Protein Binding and Correlation with Alpha 1-Acid Glycoprotein Concentration. Clin. Pharmacol. Ther. 1984; 36: 379–383
   PubMed Web of Science ®Google Scholar
• Chan G. L., Axelson J. E., Price J. D., McErlana K. M., Kerr C. R. In Vitro Protein Binding of Propafenone in Normal and Uraemic Human Sera. Eur. J. Clin. Pharmacol. 1989; 36: 495–499
   PubMed Web of Science ®Google Scholar
• Zini R., Morin D. M., Salvadori C., Tillement J.-P. Tianeptine Binding to Human Plasma Proteins and Plasma from Patients with Hepatic Cirrhosis or Renal Failure. Br. J. Clin. Pharmacol. 1990; 29: 9–18
   PubMed Web of Science ®Google Scholar
• Movin-Osswald G., Boelaert J., Hammarlund-Udenaes M., Nilsson L. B. The Pharmacokinetics of Remoxipride and Metabolites in Patients with Various Degrees of Renal Failure. Br. J. Clin. Pharmacol. 1993; 35: 615–622
   PubMed Web of Science ®Google Scholar
• Pritchard J. F., Matzke G. R., Opsahl J. A., Halstenson C. E., Nayak R. K. Effects of Hemodialysis on Plasma Protein Binding of Bepridil. J. Clin. Pharmacol. 1995; 35: 137–141
   PubMed Web of Science ®Google Scholar
• Haughey D. B., Kraft C., Matzke G. R., Halstenson C. E. Disopyramide Protein Binding in Normal and Uremic Serum [Abstract]. Clin. Pharmacol. Ther. 1983; 33: 253
   Web of Science ®Google Scholar
• Docci D., Turci F. Serum Alpha 1-Acid Glycoprotein in Uremic Patients on Hemodialysis [Letter]. Nephron 1983; 33: 72
   PubMedGoogle Scholar
• Pacifici G. M., Viani A., Rizzo G., Carrai M., Ganansia J., Bianchetti G., Morselli P. L. Plasma Protein Binding of Zolpidem in Liver and Renal Insufficiency. Int. J. Clin. Pharmacol. Ther. Toxicol. 1988; 26: 439–443
   PubMedGoogle Scholar
• Pacifici G. M., Viani A., Rizzo G., Carrai M., Rane A. Plasma Protein Binding of Clonazepam in Hepatic and Renal Insufficiency and After Hemodialysis. Ther. Drug. Monit. 1987; 9: 369–373
   PubMed Web of Science ®Google Scholar
• Barre J., Houin G., Rosenbaum J., Zini R., Dhumeaux D., Tillement J.-P. Decreased Alpha 1-Acid Glycoprotein in Liver Cirrhosis: Consequences for Drug Protein Binding [Letter]. Br. J. Clin. Pharmacol. 1984; 18: 652–653
   PubMed Web of Science ®Google Scholar
• Barre J., Mallat A., Rosenbaum J., Deforges L., Houin G., Dhumeaux D., Tillement J.-P. Pharmacokinetics of Erythromycin in Patients with Severe Liver Cirrhosis. Respective Influence of Decreased Serum Binding and Impaired Liver Metabolic Capacity. Br. J. Clin. Pharmacol. 1987; 23: 753–757
   PubMed Web of Science ®Google Scholar
• Kleger G. R., Bartsch P., Vock P., Heilig B., Roberts L. J., 2nd, Ballmer P. E. Evidence Against an Increase in Capillary Permeability in Subjects Exposed to High Altitude. J. Appl. Physiol. 1996; 81: 1917–1923
   PubMed Web of Science ®Google Scholar
• Benedek I. H., Blouin R. A., McNamara P. J. Serum Protein Binding and the Role of Increased Alpha acid Glycoprotein in Moderately Obese Male Subjects. Br. J. Clin. Pharmacol. 1984; 18: 941–946
   PubMed Web of Science ®Google Scholar
• Axelsson R., Mårtensson E., Alling C. Serum Concentration and Protein Binding of Thioridazine and Its Metabolites in Patients with Chronic Alcoholism. Eur. J. Clin. Pharmacol. 1982; 23: 359–363
   PubMed Web of Science ®Google Scholar
• Lippi G., Fedi S., Grassi M., Rossi E., Liotta A. A., Fontanelli A., Cellai A. P., Mazzanti R. Acute Phase Proteins in Alcoholics with or Without Liver Injury. Ital. J. Gastroenterol. 1992; 24: 383–385
   PubMedGoogle Scholar
• Fukui T., Hameroff S. R., Gandolfi A. J. Alpha 1-Acid Glucoprotein and Betaendorphin Alterations in Chronic Pain Patients. Anesthesiology 1984; 60: 494–496
   PubMed Web of Science ®Google Scholar
• Trovik T. S., Jaeger R., Jorde R., Ingebretsen O., Sager G. Plasma Protein Binding of Catecholamines, Prazosin and Propranolol in Diabetes Mellitus. Eur. J. Clin. Pharmacol. 1992; 43: 265–268
   PubMed Web of Science ®Google Scholar
• Pickup J. C., Crook M. A. Is Type II Diabetes Mellitus a Disease of the Innate Immune System? Association of Acute-Phase Reactants and Interleukin-6 with Metabolic Syndrome X. Diabetologia 1998; 41: 1241–1248
   PubMed Web of Science ®Google Scholar
• Anneren G., Gebre-Medhin M. Trace Elements and Transport Proteins in Serum of Children with Down's Syndrome and of Healthy Siblings Living in the Same Environment. Hum. Nutr. Clin. Nutr. 1987; 41: 291–299
   PubMedGoogle Scholar
• O'Connor P., Feely J. Clinical Pharmacokinetics and Endocrine Disorders. Therapeutic Implications. Clin. Pharmacokinet. 1987; 13: 345–364
   PubMed Web of Science ®Google Scholar
• Whicher J. T., Bell A. M., Martin M. F.P., Marshall L. A., Dieppe P. A. Prostaglandins Can Cause an Increase in Serum Acute-Phase Proteins in Man, Which Is Diminished in Systemic Sclerosis. Clin. Sci. (Colch.) 1984; 66: 165–171
   Google Scholar
• Evans M., Robertson I. G., Paxton J. W. Plasma Protein Binding of the Experimental Anti-tumor Agent, Acridine-4-carboxamide in Man, Dog, Rat and Rabbit. J. Pharm. Pharmacol. 1994; 46: 63–67
   PubMed Web of Science ®Google Scholar
• Koppel C., Wagemann A., Martens F. Pharmacokinetics and Antiarrhythmic Efficacy of Intravenous Ajmaline in Ventricular Arrhythmia of Acute Onset. Eur. J. Drug Metab. Pharmacokinet. 1989; 14: 161–167
   PubMed Web of Science ®Google Scholar
• van der Sluijs P., Meijer D. K.F. Binding of Drugs with a Quaternary Ammonium Group to Alpha 1-Acid Glygoprotein and Asialo Alpha 1-Acid Glycoprotein. J. Pharmacol. Exp. Ther. 1985; 234: 703–707
   PubMed Web of Science ®Google Scholar
• Gepts E., Heytens L., Camu F. Pharmacokinetics and Placental Transfer of Intravenous and Epidural Alfentanil in Parturient Women. Anesth. Analg. 1986; 65: 1155–1160, 1978, 26, 836A.
   PubMed Web of Science ®Google Scholar
• Dalrymple P. D., Nicholls P. J. Characterization of Aminoglutethimide Plasma Protein Binding in Man. Br. J. Clin. Pharmacol. 1985; 20: 275P–286P
   Google Scholar
• El Allaf D., Demey-Ponsart E., Pirotte J., Chapelle J.-P., El Allaf M., Van Carlier J., Cauwenberge H. The Role of Plasma Alpha 1-Acid Glycoprotein in the Binding of Aminopyrine. Arch. Int. Physiol. Biochem. 1986; 94: 317–322, (in French)
   PubMedGoogle Scholar
• Pike E., Skuterud B. Plasma Binding Variations of Amitriptyline and Nortriptyline. Clin. Pharmacol. Ther. 1982; 32: 228–234
   PubMed Web of Science ®Google Scholar
• Paxton J. W., Jurlina J. L., Foote S. E. The Binding of Amsacrine to Human Plasma Proteins. J. Pharm. Pharmacol. 1986; 38: 432–438
   PubMed Web of Science ®Google Scholar
• Li Q.-J., Peggins J. O., Fleckenstein L., Brewer T. G. Binding Characteristics of Artemisinin Drugs. FASEB J. 1998; 12: A144
   Web of Science ®Google Scholar
• Colussi D. M., Parisot C., Legay F., Lefevre G. Y. Binding of Artemether and Lumefantrine to Plasma Proteins and Erythrocytes. Eur. J. Pharm. Sci. 1999; 9: 9–16
   PubMed Web of Science ®Google Scholar
• Rosser L. M., O'Donnell A. M., Lee K. M., Morse G. D. In Vitro Protein-Binding Characteristics of Atevirdine and its N-Dealkylated Metabolite. Antiviral Res. 1994; 25: 193–200
   PubMed Web of Science ®Google Scholar
• Buch U., Isenberg E., Buch H. P. HPLC Assay for Atropine in Serum and Protein Solutions After In Vitro Addition of the Tropane Alkaloid. Methods and Findings in Exp. Clin. Pharmacol. 1994; 16: 361–365
   PubMed Web of Science ®Google Scholar
• Petersen M. C., Collier C. B., Ashley J. J., McBride W. G., Nation R. L. Disposition of Betamethasone in Parturient Women After Intravenous Administration. Eur. J. Clin. Pharmacol. 1984; 25: 803–810
   Web of Science ®Google Scholar
• Urien S., Morin D., Renouard A., Rocher I., Tillement J.-P. Variation in Serum Binding of Tertatolol Mediated by Disease-Induced Modification of Alpha-acid Glycoprotein Concentration. Eur. J. Clin. Pharmacol. 1988; 34: 381–385
   PubMed Web of Science ®Google Scholar
• Bullen W. W., Bivens D. L., Gammans R. E., LaBudde J. A. The Binding of Buspirone to Human Plasma Proteins. [Abstract]. Fed. Proc. 1985; 44: 1123
   Google Scholar
• Takamura N., Maruyama T., Ahmed S., Suenaga A., Otagiri M. Interactions of Aldosterone Antagonist Diuretics with Human Serum Proteins. Pharm. Res. 1997; 14: 522–526
   PubMed Web of Science ®Google Scholar
• Richeux F., Cascante M., Ennamany R., Saboureau D., Creppy E. E. Cytotoxicity and Genotoxicity of Capsaicin in Human Neuroblastoma Cells. Arch. Toxicol. 1999; 73: 403–409
   PubMed Web of Science ®Google Scholar
• Szallasi A., Lewin N. E., Blumberg P. M. Identification of Alpha-1-Acid Glycoprotein (Orosomucoid) as a Major Vanilloid Binding Protein in Serum. J. Pharmacol. Exp. Ther. 1992; 262: 883–888
   PubMed Web of Science ®Google Scholar
• MacKichan J. J., Zola E. M. Determinants of Carbamazepine and Carbamazepine-10,11-epoxide Binding to Serum Protein, Albumin and Alpha-1-acid Glycoprotein. Br. J. Clin. Pharmacol. 1984; 18: 487–493
   PubMed Web of Science ®Google Scholar
• Kodama Y., Kuranari M., Kodama H., Fujii I., Takeyama M. In Vivo Determinations of Carbamazepine and Carbamazepine-10,11-epoxide Binding Parameters to Serum Proteins in Monotherapy Patients. J. Clin. Pharmacol. 1993; 33: 851–855
   PubMed Web of Science ®Google Scholar
• Querol-Ferrer V., Zini R., Tillement J.-P. The Blood Binding of Cefotiam and Cyclohexanol, Metabolities of the Prodrug Cefotiam Hexetil, In-Vitro. J. Pharm. Pharmacol. 1991; 43: 863–866
   PubMed Web of Science ®Google Scholar
• Krishna S., White N. J. Pharmacokinetics of Quinine, Chloroquine and Amodiaquine. Clinical Implications. Clin. Pharmacokinet. 1996; 30: 263–299
   PubMed Web of Science ®Google Scholar
• Kornguth M. L., Hutchins L. G., Eichelman B. S. Binding of Psychotropic Drugs to Isolated Alpha1-acid Glycoprotein. Biochem. Pharmacol. 1981; 30: 2435–2441
   PubMed Web of Science ®Google Scholar
• Miyoshi T., Yamamichi R., Maruyama T., Otagiri M. Reversal of Signs of Induced Cotton Effects of Dicumarol-alpha 1-Acid Glycoprotein Systems by Phenothiazine Neuroleptics Through Ternary Complexation. Pharm. Res. 1992; 9: 845–849
   PubMed Web of Science ®Google Scholar
• Swaisland A. J., Franklin R. A. Binding of Ciclazindol by Human Plasma Involves the Glycoprotein Fraction. Biochem. Pharmacol. 1997; 26: 1361–1364
   Google Scholar
• Rovei V., Chanoine F., Strolin Benedetti M., Zini R., Tillement J.-P. Plasma Protein Binding of the Reversible Type A MAO Inhibitor Cimoxatone (MD 780515). Biochem. Pharmacol. 1983; 32: 2303–2308
   PubMed Web of Science ®Google Scholar
• Izumi T., Kitagawa T. Protein Binding of Quinolonecarboxylic Acids. J. Cinoxacin, Nalidixic Acid and Pipemidic Acid. Chem. Pharm. Bull. (Tokyo) 1989; 37: 742–745
   PubMed Web of Science ®Google Scholar
• Albertioni F., Herngren L., Juliusson G., Liliemark J. Protein Binding of 2-Chloro-2′-deoxyadenosine (Cladribine) in Healthy Subjects and in Patients with Leukemia. Eur. J. Clin. Pharmacol. 1994; 46: 563–564
   PubMed Web of Science ®Google Scholar
• Son D. S., Osabe M., Shimoda M., Kokue E. Contribution of Alpha 1-Acid Gly-coprotein to Species Differences in Lincosamides-Plasma Protein Binding Kinetics. J. Vet. Pharmacol. Ther. 1998; 21: 34–40
   PubMed Web of Science ®Google Scholar
• Bailey D. N. Cocaine and Cocaethylene Binding in Human Serum. Am. J. Clin. Pathol. 1995; 104: 180–186
   PubMed Web of Science ®Google Scholar
• Edwards D. J., Bowles S. K. Protein Binding of Cocaine in Human Serum. Pharm. Res. 1988; 5: 440–442
   PubMed Web of Science ®Google Scholar
• Mohammed S. S., Christopher M. M., Mehta P., Kedar A., Gross S., Derendorf H. Increased Erythrocyte and Protein Binding of Codeine in Patients with Sickle Cell Disease. J. Pharm. Sci. 1993; 82: 1112–1117
   PubMed Web of Science ®Google Scholar
• Howlett G. J., Roche P. J., Schreiber G. Protein–Protein Interactions: Analysis of the Interaction of Concanavalin A with Serum Glycoproteins by Sedimentation Equilibrium Using an Air-Driven, Ultracentrifuge. Arch. Biochem. Biophys. 1983; 224: 178–185
   PubMed Web of Science ®Google Scholar
• Shim H. J., Lee J. J., Lee S. D., Kim W. B., Yang J., Kim S. H., Lee M. G. Stability, Blood Partition, and Protein Binding of DA-5018, a New Nonnaracotic Analgesic. Res. Commun. Mol. Pathol. Pharmacol. 1996; 91: 97–108
   PubMed Web of Science ®Google Scholar
• Pinquier J.-L., Urien S., Chaumet-Riffaud P., Tillement J.-P. Differences in the Serum Binding Determinants of Isradipine and Darodipine—Consequences for Serum Protein Binding in Various Diseases. Br. J. Clin. Pharmacol. 1989; 28: 587–592
   PubMed Web of Science ®Google Scholar
• Chaput A. J., D'Ambrosio R., Morse G. D. In Vitro Protein-Binding Characteristics of Delvirdine and Its N-Dealkylated Metabolite. Antiviral Res. 1996; 32: 81–89
   PubMed Web of Science ®Google Scholar
• Abel J. G., Sellers E. M., Naranjo C. A., Shaw J., Kadar D., Romach M. K. Interand Intrasubject Variation in Diazepam Free Fraction. Clin. Pharmacol. Ther. 1979; 26: 247–255
   PubMed Web of Science ®Google Scholar
• Belpaire F. M., Bogaert M. G. Binding of Diltiazem to Albumin, Alpha 1-Acid Glycoprotein and to Serum in Man. J. Clin. Pharmacol. 1990; 30: 311–317
   PubMed Web of Science ®Google Scholar
• Bredesen J. R., Kierulf P. Relationship Between Alpha 1-Acid Glycoprotein and Plasma Binding of Disopyramide and Mono-N-dealkyl-disopyramide. Br. J. Clin. Pharmacol. 1984; 18: 779–784
   PubMed Web of Science ®Google Scholar
• Norris R. L., Ahokas J. T., Ravenscroft P. J., Henry M. Binding of Disopyramide to Alpha1-acid Glycoprotein in Plasma Measured by Competitive Equilibrium Dialysis. J. Pharm. Sci. 1984; 73: 824–826
   PubMed Web of Science ®Google Scholar
• Urien S., Barre J., Morin C., Paccaly A., Montay G., Tillement J.-P. Docetaxel Serum Protein Binding with High Affinity to Alpha 1-Acid Glycoprotein. Invest. New Drugs 1996; 14: 147–151
   PubMed Web of Science ®Google Scholar
• Johansen A. K., Willassen N. P., Sager G. Fluorescence Studies of Beta-adrenergic Ligand Binding to Alpha 1-Acid Glycoprotein with 1-Anilino-8-naphthalene Sulfonate, Isoprenaline, Adrenaline and Propranolol. Biochem. Pharmacol. 1992; 43: 725–729
   PubMed Web of Science ®Google Scholar
• Virtanen R., Iisalo E., Irjala K. Protein Binding of Doxepin and Desmethyldoxepin. Acta Pharmacol. Toxicol. (Copenh.) 1982; 51: 159–164
   PubMedGoogle Scholar
• Prandota J., Tillement J.-P., d'Athis Ph., Campos H., Barre J. Binding of Erythromycin Base to Human Proteins. J. Int. Med. Res. 1980; 8(Suppl. 2)1–8
   PubMedGoogle Scholar
• Smith C. D., Zilfou J. T., Zhang X., Hudes G. R., Tew K. D. Modulation of P-Glycoprotein Activity by Estramustine Is Limited by Binding to Plasma Proteins. Cancer 1995; 75: 2597–2604
   PubMed Web of Science ®Google Scholar
• Pacifici G. M., Viani A., Rizzo G. G., Carrai M. Plasma Protein Binding of Ethinyloestradiol: Effect of Disease and Interaction with Drugs. Int. J. Clin. Pharmacol. Ther. Toxicol. 1989; 27: 362–365
   PubMedGoogle Scholar
• Morgan D. J., Koay B. B., Paull J. D. Plasma Protein Binding of Etidocaine During Pregnancy and Labour. Eur. J. Clin. Pharmacol. 1982; 22: 451–457
   PubMed Web of Science ®Google Scholar
• Valle M., Estaban M., Rodriguez-Sasiain J. M., Calvo R., Aguirre C. Characteristics of Serum Protein Binding of Felodipine. Res. Commun. Mol. Pathol. Pharmacol. 1996; 94: 73–88
   PubMed Web of Science ®Google Scholar
• Tse F. L.S., Nickerson D. F., Yardley W. S. Blood and Plasma Protein Binding of Fluvastatin. [Abstract]. Int. J. Clin. Pharmacol. Ther. Toxicol. 1992; 30: 305–306
   Google Scholar
• Lai C. M., Moore P., Quon C. Y. Binding of Fosphenytoin, Phosphate Ester Prodrug of Phenytoin, to Human Serum Proteins and Competitive Binding with Carbamazepine, Diazepam, Phenobarbital, Phenylbutazone, Phenytoin, Valproic Acid or Warfarin. Res. Commun. Mol. Pathol. Pharmacol. 1995; 88: 51–62
   PubMed Web of Science ®Google Scholar
• Hamberger C., Barre J., Zini R., Taiclet A., Houin G., Tillement J.-P. In Vitro Binding of Gemfibrozil to Human Serum Proteins and Erythrocytes. Interactions with Other Drugs. Int. J. Clin. Pharmacol. Res. 1986; 6: 441–449
   PubMedGoogle Scholar
• Colussi D. M., Parisot C., Lefevre G. Y. Binding of Iralukast to Serum Proteins and Erythrocytes: Measurements Using Ultrafiltration and an Erythrocyte Partitioning Method. Eur. J. Pharm. Sci. 1997; 7: 167–173
   Web of Science ®Google Scholar
• Gillis J. C., Markham A. Irbesartan. A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Management of Hypertension. Drugs 1997; 54: 885–902
   PubMed Web of Science ®Google Scholar
• Woo J., Cheung W., Chan R., Chan H. S., Cheng A., Chan K. In Vitro Protein Binding of Isoniazid, Rifampicin, and Pyrazinamide to Whole Plasma Albumin, and Alpha 1-Acid Glycoprotein. Clin. Biochem. 1996; 29: 175–177
   PubMed Web of Science ®Google Scholar
• Martinez Jorda R., Rodriguez-Sasiain J. M., Suarez E., Calvo R. Serum Binding of Ketoconazole in Health and Disease. Int. J. Clin. Pharmacol. Res. 1990; 10: 271–276
   PubMedGoogle Scholar
• Christ D. D. Human Plasma Protein Binding of the Angiotensin II Receptor Antagonist Losartan Potassium (DuP 753/MK 954) and Its Pharmacologically Active Metabolite EXP3174. J. Clin. Pharmacol. 1995; 35: 515–520
   PubMed Web of Science ®Google Scholar
• Lynn K., Braithwaite R., Dawling S., Rosser R. Comparison of the Serum Protein Binding of Maprotiline and Phenytoin in Uraemic Patients on Haemodialysis. Eur. J. Clin. Pharmacol. 1981; 19: 73–77
   PubMed Web of Science ®Google Scholar
• Abramson F. P. Methadone Plasma Protein Binding: Alterations in Cancer and Displacement from Alpha1-acid Glycoprotein. Clin. Pharmacol. Ther 1982; 32: 652–658
   PubMed Web of Science ®Google Scholar
• Holmberg L., Odar-Cederlöf I., Nilsson J. L.G., Ehrnebo M., Boreus L. O. Pethidine Binding to Blood Cells and Plasma Proteins in Old and Young Subjects. Eur. J. Clin. Pharmacol. 1982; 23: 457–461
   PubMed Web of Science ®Google Scholar
• Wong Y. C., Chan K., Lau O. W., Aun C., Houghton I. T. Protein Binding Characterization of Pethidine and Norpethidine and Lack of Interethnic Variability. Methods and Findings in Exp. Clin. Pharmacol. 1991; 13: 273–279
   PubMed Web of Science ®Google Scholar
• Sjöholm I., Stjerna B. Binding of Drugs to Human Serum Albumin XVII:Irreversible Binding of Mercaptopurine to Human Serum Proteins. J. Pharm. Sci. 1981; 70: 1290–1291
   PubMed Web of Science ®Google Scholar
• Webb D., Buss D. C., Fifield R., Bateman D. N., Routledge P. A. The Plasma Protein Binding of Metoclopramide in Health and Renal Disease. Br. J. Clin. Pharmacol. 1986; 21: 334–336
   PubMed Web of Science ®Google Scholar
• Welker H. A., Wiltshire H., Bullingham R. Clinical Pharmacokinetics of Mibefradil. Clin. Pharmacokinet. 1998; 35: 405–423
   PubMed Web of Science ®Google Scholar
• Heikinheimo O., Lahteenmaki P. L., Koivunen E., Shoupe D., Croxatto H., Luukkainen T., Lahteenmaki P. Metabolism and Serum Binding of RU 486 in Women After Various Single Doses. Hum. Reprod. 1987; 2: 379–385
   PubMed Web of Science ®Google Scholar
• Grimaldi B., Barre J., Tillement J.-P. Respective Role of Mifepristone (RU486) Binding to Blood and Tissue Proteins in Its Quantitative Distribution in the Body. C.R. Acad. Sci. Ser. III 1992; 315: 93–99, (in French)
   PubMed Web of Science ®Google Scholar
• Yang J. M., Chan K., Chiang W. T. Distribution of Moricizine in Human Blood: Binding to Plasma Proteins and Erythrocytes. Ther. Drug. Monit. 1990; 12: 59–64
   PubMed Web of Science ®Google Scholar
• Patel L., Johnson A., Turner P. Nadoloi Binding to Human Serum Proteins. J. Pharm. Pharmacol. 1984; 36: 414–415
   PubMed Web of Science ®Google Scholar
• Asali L. A., Brown K. F. Naloxone Protein Binding in Adult and Foetal Plasma. Eur. J. Clin. Pharmacol. 1984; 27: 459–463
   PubMed Web of Science ®Google Scholar
• Robert L., Migne J., Santonja R., Zini R., Schmid K., Tillement J.-P. Plasma Binding of an Alpha-Blocking Agent, Nicergoline—Affinity for Serum Albumin and Native and Modified Alpha 1-Acid Glycoprotein. Int. J. Clin. Pharmacol. Ther. Toxicol. 1983; 21: 271–276
   PubMedGoogle Scholar
• Otto J., Lesko L. J. Protein Binding of Nifedipine. J. Pharm. Pharmacol. 1986; 38: 399–400
   PubMed Web of Science ®Google Scholar
• Knadler M. P., Bergstrom R. F., Callaghan J. T., Rubin A. Nizatidine, an H2-Blocker. Its Metabolism and Disposition in Man. Drug. Metab. Dispos. 1986; 14: 175–182
   PubMed Web of Science ®Google Scholar
• Uniyal J. P., Laumas K. R. Binding of Norgestrel to Human Plasma Proteins. Biochim. Biophys. Acta 1976; 427: 218–230
   PubMed Web of Science ®Google Scholar
• Karlsson M. O., Dahlstrom B. Serum Protein Binding of Noscapine: Influence of a Reversible Hydrolysis. J. Pharm. Pharmacol. 1990; 42: 140–143
   PubMed Web of Science ®Google Scholar
• Kim S. H., Kim H. J., Ryu C. K., Lee M. G. Stability, Blood Partition, and Protein Binding of NQ12, a New Naphthoquinone Derivative. Res. Commun. Mol. Pathol. Pharmacol. 1999; 104: 165–172
   PubMed Web of Science ®Google Scholar
• Callaghan J. T., Bergstrom R. F., Ptak L. R., Beasley C. M. Olanzapine. Pharmacokinetics and Pharmacodynamic Profile. Clin Pharmacokinet. 1999; 37: 177–193
   PubMed Web of Science ®Google Scholar
• Glasson S., Zini R., Tillement J.-P. Multiple Human Serum Binding of Two Thienopyridinic Derivatives, Ticlopidine and PCR 2362, and Their Distribution Between HSA, Alpha 1-Acid Glycoprotein, and Lipoproteins. Biochem. Pharmacol. 1982; 31: 831–835
   PubMed Web of Science ®Google Scholar
• Schley J. Binding of Perazine Metabolites and Phenothiazine Derivatives to Acid Alpha-1 Glycoprotein. Arzneim. Forsch. (Drug Res.) 1983; 33: 185–187, (in German)
   PubMed Web of Science ®Google Scholar
• Bree F., Nguyen P., Urien S., Resplandy G., Tillement J.-P. Specific and High Affinity Binding of Perindoprilat, But Not Perindopril to Blood ACE. Int. J. Clin. Pharmacol. Ther. Toxicol. 1992; 30: 325–330
   PubMedGoogle Scholar
• Somani S. M., Unni L. K., McFadden D. L. Drug interaction for Plasma Protein Binding: Physostigmine and Other Drugs. Int. J. Clin. Pharmacol. Ther. Toxicol. 1987; 25: 412–416
   PubMedGoogle Scholar
• Essassi D., Zini R., Hamberger C., Urien S., Rougeot C., Uzan A., Tillement J.-P. Binding In Vitro of Pipequaline (45319 RP) onto Plasma Proteins and Blood Cells in Man. Biochem. Pharmacol. 1987; 36: 3501–3507
   PubMed Web of Science ®Google Scholar
• Hamill S. C., Shand D. G., Routledge P. A., Hindman M. C., Baker J. T., Pritchett E. L.C. Pirmenol, a New Antiarrhythmic Agent: Initial Study of Efficacy, Safety and Pharmacokinetics. Circulation 1982; 65: 369–375
   PubMed Web of Science ®Google Scholar
• Sakai T., Adachi Y., Yatomi M., Awata N. Contributions of Various Serum Proteins to the Binding of Prasterone Sulfate in Humans. Chem. Pharm. Bull. (Tokyo) 1992; 40: 2864–2865
   PubMed Web of Science ®Google Scholar
• Milsap R. L., Jusko W. J. Binding of Prednisolone to Alpha 1-Acid Glycoprotein. J. Steroid Biochem. 1983; 18: 191–194
   PubMedGoogle Scholar
• Wong A. K., Hsia J. C. In Vitro Binding of Propranolol and Progesterone to Native and Desialylated Human Orosomucoid. Can. J. Biochem. Cell Biol. 1983; 61: 1114–1116
   PubMedGoogle Scholar
• Zini R., Barre J., Defer G., Jeanniot J. P., Houin G., Tillement J.-P. Protein Binding of Propisomide. J. Pharm. Sci. 1985; 74: 530–533
   PubMed Web of Science ®Google Scholar
• Garrido M. J., Jimenez R. M., Rodriguez-Sasiain J. M., Aguirre C., Calvo R. Characterization of Propofol Binding to Plasma Proteins and Possible Interactions. Rev. Esp. Anestesiol. Reanim. 1994; 41: 308–312, (in Spanish)
   PubMedGoogle Scholar
• Verbeeck R. K., Cardinal J. A. Plasma Protein Binding of Salicylic Acid, Phenytoin, Chlorpromazine, Propranolol, and Pethidine Using Equilibrium Dialysis and Ultracentrifugation. Arzeneimittel-Forschung 1985; 35: 903–906
   PubMed Web of Science ®Google Scholar
• Oravcova J., Bystricky S., Trnovec T. Different Binding of Propranolol Enantiomers to Human Alpha 1-Acid Glycoprotein. Biochem. Pharmacol. 1989; 38: 2575–2579
   PubMed Web of Science ®Google Scholar
• Edwards D. M., Pellizzoni C., Breuel H. P., Berardi A., Castelli M. G., Frigerio E., Poggesi I., Rocchetti M., Dubini A., Strolin Benedetti M. Pharmacokinetics of Reboxetine in Healthy Volunteers. Single Oral Doses, Linearity and Plasma Protein Binding. Biopharm. Drug Dispos. 1995; 16: 443–460
   PubMed Web of Science ®Google Scholar
• Gross A. S., Brown K. F. Plasma Protein Binding of Ritodrine at Parturition and in Non-Pregnant Women. Eur. J. Clin. Pharmacol. 1985; 28: 479–481
   PubMed Web of Science ®Google Scholar
• Urien S., Nguyen P., Bastian G., Lucas C., Tillement J.-P. Binding of a New Multidrug Resistance Modulator, S9788, to Human Plasma Proteins and Erythrocyte. Invest. New Drugs 1995; 13: 37–41
   PubMed Web of Science ®Google Scholar
• Makela P. M., Truman C. A., Ford J. M., Roberts C. J. Characteristics of Plasma Protein Binding of Tacrine Hydrochloride: A New Drug for Alzheimer's Disease. Eur. J. Clin. Pharmacol. 1995; 47: 151–155
   Web of Science ®Google Scholar
• Piekoszewski W., Jusko W. J. Plasma Protein Binding of Tacrolimus in Humans. J. Pharm. Sci. 1993; 82: 340–341
   PubMed Web of Science ®Google Scholar
• Nagasaki K., Iwasaki K., Nozaki K., Noda K. Distribution and Protein Binding of FK 506, a Potent Immunosuppressive Macrolide Lactone in Human Blood and Its Uptake by Erythrocytes. J Pharm Pharmacol. 1994; 46: 113–117
   PubMed Web of Science ®Google Scholar
• Matsushima H., Kamimura H., Sueishi Y., Watanabe T., Higuchi S. Plasma Protein Binding of Tamsulosin Hydrochloride in Renal Disease: Role of Alpha 1-Acid Glycoprotein and Possibility of Binding Interactions. Eur. J. Clin. Pharmacol. 1999; 55: 437–443
   PubMed Web of Science ®Google Scholar
• Kumar G. N., Walle U. K., Bhalla K. M., Walle T. Binding of Taxol to Human Plasma, Albumin, and Alpha 1-Acid Glycoprotein. Res. Commun. Chem. Pathol. Pharmacol. 1993; 80: 337–344
   PubMedGoogle Scholar
• George S., McBurney A., Ward J. The Protein Binding of Timegadine Determined by Equilibrium Dialysis. Br. J. Clin. Pharmacol. 1984; 18: 785–790
   PubMed Web of Science ®Google Scholar
• Sipila H., Nanto V., Kangas L., Antilla M. Halme, Binding of Toremifene to Human Serum Proteins. Pharmacol. Toxicol. 1988; 63: 62–64
   PubMedGoogle Scholar
• Colussi D. M., Parisot C., Rossolino M. L., Brunner L. A., Lefevre G. Y. Protein Binding in Plasma of Valsartan, a New Angiotensin II Receptor Antagonist. J. Clin. Pharmacol. 1997; 37: 214–221
   PubMed Web of Science ®Google Scholar
• McGowan F. X., Reiter M. J., Pritchett E. L.C., Shand D. G. Verapamil Plasma Binding: Relationship to Alpha1-acid Glycoprotein and Drug Efficacy. Clin. Pharmacol. Ther. 1983; 33: 485–490
   PubMed Web of Science ®Google Scholar
• Steele W. H., Haughton D. J., Barber H. E. Binding of Vinblastine to Recrystallized Human Alpha 1-Acid Glycoprotein. Cancer Chemother. Pharmacol. 1982; 10: 40–42
   PubMed Web of Science ®Google Scholar
• Urien S., Bastian G., Lucas C., Bizzari J. P., Tillement J.-P. Binding of a New Vinca Alkaloid Derivative, S12363, to Human Plasma Proteins and Platelets. Invest. New Drugs 1992; 10: 263–268
   PubMed Web of Science ®Google Scholar
• Luzier A., Morse G. D. Intravascular Distribution of Zidovudine: Role of Plasma Proteins and Whole Blood Components. Antiviral Res. 1993; 21: 267–280
   PubMed Web of Science ®Google Scholar
• Machinist J. M., Kukulka M. J., Bopp B. A. In Vitro Plasma Protein Binding of Zileutin and N-Dehydroxylated Metabolite. Clin. Pharmacokinet. 1995; 2(Suppl. 2)34–41
   Google Scholar